var title_f13_37_13904="Shh Gli pathway medulloblastoma";
var content_f13_37_13904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    The Shh-Gli pathway and potential sites for blocking it with therapeutic agents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 429px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonic hegehog (Shh) acts on the membrane receptor complex formed by Patched (Ptc) and Smoothened (Smo) to inhibit the repression of Smo by Ptc. Smo is then thought to send the signal intracellularly through several cytoplasmic transduction steps (not shown), leading to the nuclear action of the Gli proteins, which regulate target genes. Thick blue arrows pointing up or down indicate activating or inactivating mutations, respectively, that might induce the pathway. Inhibitors of the the pathway with potential therapeutic value (red lines) include: agents that block the action of Smo in the receptor complex, such as the plant alkaloid cyclopamine; agents that inhibit specific aspects of the transduction of the signal, including the nuclear import or activation of Gli proteins; and agents that specifically inhibit Gli function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ataba, AR, Sanchez, P Dahmane, N. Gli and Hedgehog in Cancer: Tumours, Embryos and Stem Cells. Nat Rev Cancer 2002; 2:361. Copyright &copy; 2002 Nature Publishing Group.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13904=[""].join("\n");
var outline_f13_37_13904=null;
var title_f13_37_13905="FDG PET CT lung";
var content_f13_37_13905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FDG-PET/CT of a malignant lung mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The image demonstrates a malignant lung mass as seen on an integrated 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) scan. The increased activity of the mass is the result of the uptake and accumulation of FDG by the metabolically active tumor cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13905=[""].join("\n");
var outline_f13_37_13905=null;
var title_f13_37_13906="Bucket handle fx distal tib";
var content_f13_37_13906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Bilateral bucket handle metaphyseal fractures of the distal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 3-month-old child with bilateral ankle swelling was found to have bilateral metaphyseal \"bucket-handle\" type fractures (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eglal Shalaby-Rana, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13906=[""].join("\n");
var outline_f13_37_13906=null;
var title_f13_37_13907="Selenium: Drug information";
var content_f13_37_13907=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Selenium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/3/2100?source=see_link\">",
"    see \"Selenium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      SE Aspartate [OTC];",
"     </li>",
"     <li>",
"      Se-100 [OTC];",
"     </li>",
"     <li>",
"      Selenicaps;",
"     </li>",
"     <li>",
"      Selenimin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Trace Element, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Nutritional supplement:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Recommended daily allowance (RDA):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 55 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pregnancy: 60 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lactation: 70 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      I.V. in TPN solutions:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolically stable: 20-40 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Deficiency from prolonged TPN support: 100 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nutritional supplement:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Adequate intake (AI):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-6 months: 15 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     7-12 months: 20 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Recommended daily allowance (RDA):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-3 years: 20 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     4-8 years: 30 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     9-13 years 40 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;14 years: 55 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. in TPN solutions: 3 mcg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 200 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Se-100: 100 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selenicaps: 200 mcg [gluten free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 40 mcg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mcg, 100 mcg, 200 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SE Aspartate: 50 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selenimin: 50 mcg [contains calcium 115 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selenimin: 125 mcg, 200 mcg [gluten free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral: 200 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trace metal supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Local: Irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Undiluted administration into peripheral vein",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13879888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal dysfunction: Use with caution in patients with GI impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aluminum: Solution for injection contains aluminum; use with caution in patients with impaired renal function and in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Selenium may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., selenium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13879886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were seen with high doses in animal studies. Selenium is found in the placenta and cord blood. Teratogenic effects have not been observed with nontoxic doses in humans (IOM, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13879887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selenium is found in breast milk. Concentrations vary based on maternal intake and time postpartum. Adverse events have not been observed with nontoxic maternal intake in humans (IOM, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Selenium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (50): $4.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Aqueous Selenium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95 mcg/drop (15 mL): $12.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Selenium ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (60): $4.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Selenium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $3.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (100): $4.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $5.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vitaline Selenium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (90): $6.90",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cerosel (PL);",
"     </li>",
"     <li>",
"      Selenium Microsol (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Part of glutathione peroxidase which protects cell components from oxidative damage due to peroxidases produced in cellular metabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Urine, feces, lungs, skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids",
"      </i>",
"      ,  Washington, DC: National Academy Press, 2000.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9884 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-1E13E97D75-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13907=[""].join("\n");
var outline_f13_37_13907=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220384\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220390\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220385\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220387\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220386\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220377\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220366\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220378\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220388\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220381\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13879888\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300033\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220374\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220375\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13879886\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13879887\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323826\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301440\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220369\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220380\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/3/2100?source=related_link\">",
"      Selenium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13908="Hodgkin lymphoma in adults";
var content_f13_37_13908=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/37/13908/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13908/contributors\" id=\"au4695\">",
"       Peter M Mauch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/37/13908/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13908/contributors\" id=\"se4525\">",
"       Arnold S Freedman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/37/13908/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13908/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/37/13908?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Hodgkin lymphoma (formerly called Hodgkin's disease) is a cancer of the body's lymphatic system. Lymphomas are cancers of lymphocytes, a type of white blood cell that is important in the immune system.",
"    </p>",
"    <p>",
"     The lymphatic system is a network of lymph nodes and interconnecting lymph vessels (",
"     <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"      figure 1",
"     </a>",
"     ). Lymph nodes are small, bean-shaped organs that make and store lymphocytes, a type of white blood cell that fights infection. Lymph vessels are similar to blood vessels and carry a watery fluid (lymphatic fluid) that contains lymphocytes.",
"    </p>",
"    <p>",
"     In Hodgkin lymphoma, a cancerous tumor develops in a lymph node, usually in the neck or chest. If Hodgkin lymphoma spreads, it usually spreads first to nearby lymph nodes, and then to the spleen, liver, or bone marrow. As it progresses, Hodgkin lymphoma can affect the body's ability to fight infection. The exact cause of Hodgkin lymphoma is not known in most cases.",
"    </p>",
"    <p>",
"     Fortunately, Hodgkin lymphoma is one of the most treatable forms of cancer. About 75 percent of people diagnosed with Hodgkin lymphoma can be cured with treatment. Over 90 percent of people live at least 10 years after treatment.",
"    </p>",
"    <p>",
"     More detailed information about Hodgkin lymphoma is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"      \"Staging and prognosis of Hodgkin lymphoma\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"      \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"      \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"      \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HODGKIN LYMPHOMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with Hodgkin lymphoma are diagnosed because of a painless, enlarged lymph node in the neck. Enlarged nodes may also be found above the collar bone, in the armpit (axilla), or the groin (inguinal) area (",
"     <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Some people are diagnosed with a mass in the chest, which causes a cough, chest discomfort, or shortness of breath. There may also be symptoms of fever, night sweats, and weight loss. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"      \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If your doctor or nurse is concerned that you could have Hodgkin lymphoma, you should see a physician who specializes in cancer treatment (called a",
"     <span class=\"nowrap\">",
"      hematologist/oncologist)",
"     </span>",
"     for further testing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HODGKIN LYMPHOMA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Tissue biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have symptoms of Hodgkin lymphoma, you will need surgery to remove an enlarged lymph node. This is usually done as a day surgery procedure. After removal, the lymph node is examined to see whether it contains any signs of lymphoma. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"      \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Bone marrow biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A bone marrow biopsy might be recommended if your doctor suspects that Hodgkin lymphoma is advanced, if you have fever, weight loss,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     night sweats, or if you have an abnormal blood count. This test determines whether there are lymphoma cells in the bone marrow, which indicates an advanced stage of Hodgkin lymphoma.",
"    </p>",
"    <p>",
"     A bone marrow biopsy involves removing a sample of bone marrow fluid, usually from the pelvic or hip bone. You will be given medicine to reduce pain during the procedure. The bone marrow fluid is then examined under a microscope to determine whether it is involved with Hodgkin lymphoma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HODGKIN LYMPHOMA STAGING",
"     </span>",
"    </p>",
"    <p>",
"     Staging involves dividing people with Hodgkin lymphoma into groups (stages) based upon certain criteria at the time of diagnosis. Treatment decisions are based in large part on the stage of disease that is found. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"      \"Staging and prognosis of Hodgkin lymphoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The following are terms used in the staging criteria:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lymph node regions: An area of lymph nodes and the surrounding tissue. Examples include the cervical nodes in the neck, the axillary nodes in the armpit, the inguinal nodes in the groin, or the mediastinal nodes in the chest (",
"       <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Lymph structures: Organs or structures that are part of the lymphatic system, such as the lymph nodes, spleen, and thymus gland (",
"       <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"        figure 1",
"       </a>",
"       ). These organs or structures play a role in the body's immune system.",
"      </li>",
"      <li>",
"       Diaphragm: A large muscle that separates the chest from the abdomen.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The stage of Hodgkin lymphoma is based upon:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The number of lymph node regions or structures that are involved",
"      </li>",
"      <li>",
"       The location of the affected lymph node regions or structure (one or both sides of the diaphragm)",
"      </li>",
"      <li>",
"       Whether there are signs of cancer outside the lymphatic system (eg, in the liver, lung, or bone marrow)",
"      </li>",
"      <li>",
"       Whether you have unexplained fever, night sweats, or weight loss (called \"B symptoms\")",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Hodgkin lymphoma stages range from stage I (only one lymph node region or structure is involved) to stage IV (the cancer has spread beyond the lymphatic system) (",
"     <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In general, lower-stage cancers are more likely to be cured and less likely to come back after treatment compared with higher-stage cancers. Stage I and II Hodgkin lymphoma are referred to as early stage, while stage III and IV Hodgkin lymphoma are referred to as advanced.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Subclassifications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Additional criteria help to further identify subgroups within each stage, as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A or B &mdash; The letter \"A,\" as in stage IIA, means that symptoms of unexplained fever, night sweats, or weight loss (at least 10 percent of the body weight) were NOT present during the six months prior to diagnosis. The letter \"B,\" as in stage IIIB, means that these symptoms were present. These symptoms are therefore referred to as \"B symptoms.\"",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For example, a person with Hodgkin lymphoma involving lymph nodes in the neck, mediastinum, and groin (ie, involvement above and below the diaphragm) who also has symptoms of fever, night sweats, and weight loss has stage IIIB disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Tests used in staging",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of tests are used in the process of staging. These tests help determine which areas of the body have been affected by Hodgkin lymphoma. However, not all patients will require every test. Tests that may be done include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood tests",
"      </li>",
"      <li>",
"       CT or PET scan of the chest, abdomen, and pelvic area",
"      </li>",
"      <li>",
"       Bone marrow biopsy: removal of tissue from the bone marrow, the spongy area in the middle of large bones",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HODGKIN LYMPHOMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The main treatments for Hodgkin lymphoma are chemotherapy and radiation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is a treatment given to stop the growth of cancer cells. Most treatments involve a combination of several chemotherapy drugs (called regimens). Most of the drugs are given into the vein (intravenous, IV).",
"    </p>",
"    <p>",
"     Chemotherapy is not typically given every day but instead is given in cycles. A cycle of chemotherapy (which is typically 21 or 28 days) refers to the time it takes to give the treatment and then allow the body to recover from the side effects of the medicines.",
"    </p>",
"    <p>",
"     For example, two doses of ABVD chemotherapy (see below) are given 14 days apart to make up one cycle of treatment. If this regimen were repeated for a total of four cycles, it would take up to four months to complete.",
"    </p>",
"    <p>",
"     Chemotherapy regimens for Hodgkin lymphoma include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       ABVD &mdash; ABVD includes Adriamycin&reg; (doxorubicin), bleomycin, vinblastine, and dacarbazine. ABVD is the most commonly used chemotherapy regimen.",
"      </li>",
"      <li>",
"       Stanford V &mdash; Stanford V includes Adriamycin&reg;, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone.",
"      </li>",
"      <li>",
"       BEACOPP &mdash; BEACOPP includes bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin&reg;, procarbazine, and prednisone. This regimen is more commonly used in Europe. Some experts feel that BEACOPP is more effective than other regimens, especially in people with more advanced disease. However, it has more toxic side effects, which some people cannot tolerate.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The type and severity of chemotherapy side effects depend upon the combination and dose of chemotherapy medicines given. The most common treatment-related side effects include temporary hair loss, nausea, vomiting, fatigue, loss of appetite, increased risk of infections, and becoming bruised or bleeding easily. Many of these side effects can be prevented or treated.",
"    </p>",
"    <p>",
"     Long-term side effects of chemotherapy include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infertility &mdash; Some types of chemotherapy can damage a woman's oocytes (eggs). If most or all of the eggs are damaged or destroyed, a woman will go through an early menopause. This means that her periods will stop permanently, and she will have infertility because her eggs are damaged or gone.",
"       <br/>",
"       <br/>",
"       Early menopause, sometimes called \"premature ovarian failure\" or \"primary ovarian insufficiency,\" is most common with BEACOPP chemotherapy. About 50 percent of women lose their periods permanently after receiving BEACOPP. In contrast, ABVD chemotherapy does not seem to damage the ovaries.",
"       <br/>",
"       <br/>",
"       The pattern is similar in men. BEACOPP chemotherapy causes very low sperm counts and infertility, but ABVD treatment does not.",
"      </li>",
"      <li>",
"       Lung damage &mdash; Bleomycin, which is used in all treatment regimens, can damage the lungs; this risk is highest in people who have radiation therapy to the chest.",
"      </li>",
"      <li>",
"       Secondary cancer &mdash; There is a risk of developing a second cancer years after the first treatment for Hodgkin lymphoma. The most common secondary cancers include those of the breast, lung, or gastrointestinal system. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"        \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Some forms of radiation therapy increase the risk of developing cancer in areas that were treated (such as to the lungs and breast tissue) years after therapy is finished. Women under 30 are at increased risk of breast cancer, and smokers have an increased risk of lung cancer (beyond the already increased risk of lung cancer from smoking). It is also possible to develop leukemia or other types of lymphoma.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy (RT) involves using high-energy X-rays to stop the growth of cancer cells. Unlike normal cells, cancer cells cannot repair the damage caused by exposure to X-rays over several days. This prevents the cancer cells from growing further and causes them to eventually die.",
"    </p>",
"    <p>",
"     Radiation therapy is sometimes recommended to treat Hodgkin lymphoma, usually after finishing chemotherapy. The radiation is directed to the area of affected lymph nodes with a carefully focused beam of radiation; this is called involved field radiation. Radiation therapy must be given in small daily doses over a period of weeks to minimize the side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;During radiation treatment, some people develop skin changes in the area that was treated, similar to a sunburn. These changes fade over time. Other side effects can include fatigue and nausea.",
"    </p>",
"    <p>",
"     You and your healthcare provider should discuss the risks and benefits of radiation therapy when deciding on a treatment plan. Limiting the radiation dose and area treated can reduce, but not totally eliminate, these risks. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"      \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Stage I or II",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with stage I or II disease are usually treated with chemotherapy with radiation or, in some cases, chemotherapy alone. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"      \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"      \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Using chemotherapy along with radiation has a lower relapse rate than using chemotherapy alone, and it might improve survival. However, having chemotherapy and radiation therapy can have more late side effects. Discuss the risks and benefits of these options with your doctor or nurse; your understanding and involvement are an important part of your cancer care.",
"    </p>",
"    <p>",
"     The challenge of managing Hodgkin lymphoma is that there are risks of long-term complications related to the treatment, which can affect survival. After finishing treatment for Hodgkin lymphoma, you should work with your doctor to monitor for and prevent new cancers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Stage III and IV",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common treatment for people with stage III and IV Hodgkin lymphoma is chemotherapy. Radiation therapy may be added if the tumor was large at the time of diagnosis or if there are areas of tumor that have not completely responded to chemotherapy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"      \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most people with stage III and IV disease will be given the ABVD regimen. With this, 60 to 70 percent of patients will be alive and free of disease at five years. ABVD alone is the treatment of choice for most patients with advanced disease, although Stanford V and BEACOPP, combined with radiation, are reasonable alternatives for some people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Hematopoietic stem cell transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hematopoietic stem cell transplantation (also known as bone marrow transplantation) might be offered to people who have:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Recurrent Hodgkin lymphoma",
"      </li>",
"      <li>",
"       Hodgkin lymphoma that is resistant to other forms of treatment. This includes people whose disease relapses after the first round of treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A separate article discusses bone marrow transplantation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=see_link\">",
"      \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Many people with Hodgkin lymphoma will be asked about enrolling in a clinical (research) trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask your doctor or nurse for more information, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804493118\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3046388697\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=see_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/50/31523?source=see_link\">",
"      Patient information: Hodgkin lymphoma in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3046388724\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=see_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"      Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=see_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=see_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"      The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link\">",
"      The role of Epstein-Barr virus in Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=see_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"      Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/types/hodgkin\">",
"      www.cancer.gov/cancertopics/types/hodgkin",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/37/13908?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_37_13908=[""].join("\n");
var outline_f13_37_13908=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HODGKIN LYMPHOMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HODGKIN LYMPHOMA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HODGKIN LYMPHOMA STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HODGKIN LYMPHOMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\" title=\"figure 1\">",
"           Lymphatic system PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19836\" title=\"table 1\">",
"           Cotswolds system in HL",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13909="Ferric gluconate: Pediatric drug information";
var content_f13_37_13909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferric gluconate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"    see \"Ferric gluconate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/39/39539?source=see_link\">",
"    see \"Ferric gluconate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrlecit&reg;;",
"     </li>",
"     <li>",
"      Nulecit&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrlecit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1013799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1013826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"      see \"Ferric gluconate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering",
"     </b>",
"     ; incorrect selection or substitution of one form for another without proper dosage adjustment may result in serious over- or under-dosing; test doses are recommended before starting therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Per National Kidney Foundation DOQI Guidelines, initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. There is insufficient evidence to recommend I.V. iron if ferritin level &gt;500 ng/mL. Dosage expressed in mg",
"     <b>",
"      elemental",
"     </b>",
"     iron: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;6 years: 1.5 mg/kg (0.12 mL/kg Ferrlecit&reg;) repeated at each of 8 sequential dialysis sessions not to exceed 125 mg (10 mL) per dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 125 mg (10 mL) during hemodialysis; most patients will require a cumulative dose of 1 g over ~8 sequential dialysis treatments to achieve a favorable response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A test dose (25 mg in adult patients) previously recommended in product literature is no longer listed. No pediatric test dose has been recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Elemental iron 12.5 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrlecit&reg;: Elemental iron 12.5 mg/mL (5 mL) [contains benzyl alcohol, sucrose 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nulecit&trade;: Elemental iron 12.5 mg/mL (5 mL [DSC]) [contains benzyl alcohol, sucrose ~20%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1013830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Avoid dilution in dextrose due to an increased incidence of local pain and phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion: If a test dose is used, dilute in 50 mL NS and infuse over 1 hour; dilute repletion dose in 25-100 mL NS and infuse over at least 1 hour; do not exceed 12.5 mg/minute; not for I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Slow I.V. injection: 1 mL (12.5 mg iron) of undiluted solution per minute (5 minutes/vial)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1013821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatible",
"     </b>",
"     with 0.9% sodium chloride; do not mix with parenteral nutrition solutions or other medications.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1013817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not freeze; use immediately after dilution in NS. Product literature states parenteral iron formulations should not be mixed with other medications or in parenteral nutrition solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1013800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of microcytic, hypochromic anemia resulting from iron deficiency in combination with erythropoietin in hemodialysis patients when iron administration is not feasible or ineffective",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ferric gluconate may be confused with ferumoxytol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, bradycardia, chest pain, edema, hyper-/hypotension, hypervolemia, MI, peripheral edema, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation, chills, consciousness decreased, dizziness, fatigue, fever, headache, lightheadedness, malaise, rigors, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyper-/hypokalemia, hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, eructation, flatulence, GI disorder, melena, nausea, rectal disorder, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Menorrhagia, UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, erythrocytes abnormal (changes in morphology/color/number), leukocytosis, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arm pain, arthralgia, back pain, cramps, leg cramps, leg edema, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Arcus senilis, conjunctivitis, diplopia, puffy eyelids, redness of eyes, rolling of eyes, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Deafness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, pneumonia, pulmonary edema, rhinitis, upper respiratory infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Abscess, carcinoma, diaphoresis, flu-like symptoms, infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactic reactions, convulsion, facial flushing, hemorrhage, hypertonia, hypoesthesia, loss of consciousness, shock, skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1013804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to the iron formulation or any component; anemias that are not associated with iron deficiency; hemochromatosis; hemolytic anemia; iron overload",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5275939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with histories of significant allergies, asthma, hepatic impairment, rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1013805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deaths associated with parenteral iron administration following anaphylactic-type reactions have been reported; treatment agents for anaphylactic reactions (eg, epinephrine, steroids, diphenhydramine) should be immediately available; a test dose is recommended prior to initial therapy; rapid I.V. administration is associated with flushing, fatigue, weakness, hypotension, and chest, back, groin, or flank pain; use parenteral iron only in patients where the iron deficient state is not amenable to oral iron therapy; ferric gluconate is not approved for I.M. administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ferric gluconate contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites; avoid use of ferric gluconate formulation in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1013832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs and other symptoms of anaphylactoid reactions (during I.V. infusion); reticulocyte count, serum ferritin, hemoglobin, serum iron concentrations, and transferrin saturation (TSAT).  Ferritin and TSAT may be inaccurate if measured within 14 days of receiving a large single dose (1000 mg in adults).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F5275941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Male: 75-175 mcg/dL; female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Percent transferrin saturation (TSAT): 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic kidney disease (CKD): Targets for iron therapy (KDOQI Guidelines, 2007) to maintain Hgb 11-12 g/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:  Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1013822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces iron found in hemoglobin, myoglobin, and specific enzymes; allows transportation of oxygen via hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5275940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1013824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Following I.V. doses, the uptake of iron by the reticuloendothelial system appears to be constant at about 40-60 mg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 1.31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: By the reticuloendothelial system and excreted in urine and feces (via bile)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5275943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron storage may lag behind the appearance of normal red blood cell morphology; use periodic hematologic determination to assess therapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):471-530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/37/13909/abstract-text/17720528/pubmed\" id=\"17720528\" target=\"_blank\">",
"        17720528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seligman PA, Dahl NV, Strobos J, et al, \"Single-Dose Pharmacokinetics of Sodium Ferric Gluconate Complex in Iron-Deficient Subjects,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(5):574-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/37/13909/abstract-text/15162891/pubmed\" id=\"15162891\" target=\"_blank\">",
"        15162891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Zobrist RH, Wu J, et al, \"Sodium Ferric Gluconate Complex Therapy in Anemic Children on Hemodialysis,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2005, 20(9):1320-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/37/13909/abstract-text/15971073/pubmed\" id=\"15971073\" target=\"_blank\">",
"        15971073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13053 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-83C8AEB15F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13909=[""].join("\n");
var outline_f13_37_13909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170704\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855041\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013799\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013826\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170691\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170676\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013830\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013821\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013817\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013800\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170728\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170725\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013804\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275939\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013805\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299320\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170685\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170687\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170697\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013832\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275941\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013822\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275940\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013824\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275943\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=related_link\">",
"      Ferric gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/39/39539?source=related_link\">",
"      Ferric gluconate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13910="Epidemiology and pathogenesis of Wilson disease";
var content_f13_37_13910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of Wilson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Michael L Schilsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13910/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/37/13910/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease (hepatolenticular degeneration) results from a defect in cellular copper transport, leading to the accumulation of copper in the liver and other tissues, including the brain. Over time, the damage from the accumulation of copper results in the hepatic, neurologic, and psychiatric manifestations of Wilson disease.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology and pathogenesis of Wilson disease. The clinical manifestations, diagnosis, and treatment of Wilson disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158657485\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease is found worldwide, with an estimated prevalence of 1 case per 30,000 live births in most populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 1 person in 90 carries an abnormal copy the",
"    <em>",
"     ATP7B",
"    </em>",
"    gene. However, in some populations, the prevalence is much higher. One of the highest reported prevalences was from a small mountain village on the island of Crete, where Wilson disease was diagnosed in 1 in 15 births [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/2\">",
"     2",
"    </a>",
"    ]. The increased prevalence was likely due to high rates of consanguinity in the isolated area.",
"   </p>",
"   <p>",
"    Some studies suggest that men and women are equally affected, though women are more likely than men to develop acute liver failure due to Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, a large registry study of 627 patients with Wilson disease found that there was a slight male predominance (52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/5\">",
"     5",
"    </a>",
"    ]. At the time of diagnosis, among patients who were symptomatic, men were more likely than women to have neuropsychiatric disease (75 versus 58 percent) and were less likely to have hepatic disease (25 versus 41 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69501971#H69501971\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Acute hepatitis and acute liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3905564\">",
"    <span class=\"h1\">",
"     COPPER METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary copper intake is approximately 1 to 2 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/6\">",
"     6",
"    </a>",
"    ]. Copper is absorbed in the stomach and duodenum, binds mainly to circulating albumin, and is taken up by various tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The daily requirement for copper is approximately 0.75 mg. Excess copper is predominantly excreted into the bile, where it ends up as fecal copper. Renal losses account for only 5 to 15 percent of the daily excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of dietary trace minerals\", section on 'Copper'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The transport of copper within hepatocytes is regulated by ATP7B, the copper transporting intracellular protein affected in Wilson disease. ATP7B is expressed mainly in hepatocytes and is normally found in two subcellular locations: in the trans-Golgi network and in cytoplasmic vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In the trans-Golgi network, ATP7B mediates the transport of copper for incorporation of six copper molecules into apoceruloplasmin to form ceruloplasmin. Ceruloplasmin is then secreted into plasma. Copper in ceruloplasmin is not exchangeable under physiologic conditions (copper in this molecule is necessary for its function in iron metabolism as a \"ferroxidase\") and accounts for about 90 percent of the circulating copper. In the cytoplasmic vesicles, ATP7B mediated copper transport sequesters excess copper in these pre-lysosomal vesicles which are then excreted into bile via exocytosis across the hepatocyte apical canalicular membrane. There has been some suggestion that the ATP7B protein may itself be localized to the canaliculus for the function of copper transport into bile; however, this is controversial.",
"   </p>",
"   <p>",
"    Disorders in copper transport result in disease related to either copper deficiency or copper excess:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Menkes disease, a fatal X-linked genetic disorder characterized by progressive neurodegeneration. In Menkes disease, there is a defect in ATP7A, a homologous protein to ATP7B, that reduces the transport of copper from the intestine and internally in other tissues, effectively causing copper malabsorption and maldistribution leading to a copper deficiency state [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of dietary trace minerals\", section on 'Menkes disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In Wilson disease, there is decreased incorporation of copper into ceruloplasmin and decreased transport of copper from the liver into bile, leading to copper excess despite low circulating levels of ceruloplasmin (the major form of circulating copper).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genes encoding the defective proteins for these two disorders are highly homologous, and cloning of the gene for Menkes disease,",
"    <em>",
"     ATP7A",
"    </em>",
"    , led to cloning of the gene for Wilson disease,",
"    <em>",
"     ATP7B",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3906210\">",
"     'Genetic defect in Wilson disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3906210\">",
"    <span class=\"h1\">",
"     GENETIC DEFECT IN WILSON DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease is an autosomal recessive disorder and is the result of mutation in",
"    <em>",
"     ATP7B",
"    </em>",
"    , a gene encoding a hepatic copper transport protein (ATP7B) on chromosome 13. (See",
"    <a class=\"local\" href=\"#H3905564\">",
"     'Copper metabolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Using positional cloning and information deduced by homology with the Menkes disease gene (",
"    <em>",
"     ATP7A",
"    </em>",
"    ), the sequence of the Wilson disease protein was determined and named \"",
"    <em>",
"     ATP7B",
"    </em>",
"    \" [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of dietary trace minerals\", section on 'Menkes disease'",
"    </a>",
"    .) ATP7B is a P-type ATPase that binds copper at the N-terminal domain and is responsible for the transport of copper across cellular membranes, using ATP as an energy source.",
"   </p>",
"   <p>",
"    ATP7B can be affected by mutations at many different sites. Over 300 different mutations in the",
"    <em>",
"     ATP7B",
"    </em>",
"    gene have been identified in patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/1\">",
"     1",
"    </a>",
"    ]. The H1069Q mutation is one of the most common mutations, with an allelic frequency of 10 to 40 percent (30 to 70 percent among Caucasians) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Most patients are compound heterozygotes, carrying different mutations on each copy of chromosome 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in",
"    <em>",
"     ATP7B",
"    </em>",
"    in Wilson disease impair both the incorporation of copper into apoceruloplasmin and the excretion of copper into bile, bile, the latter reducing the major pathway of copper elimination that is responsible for the clinical manifestations and pathology of Wilson disease. (See",
"    <a class=\"local\" href=\"#H3905564\">",
"     'Copper metabolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The impaired incorporation of copper into apoceruloplasmin leads to secretion of apoceruloplasmin peptide that is folded differently than the holoprotein with its complement of copper. The differently-folded protein has a shorter half life in the circulation, thereby reducing steady state circulating levels of this protein. However, low serum ceruloplasmin concentrations do not play a role in the clinical manifestations of Wilson disease, though they are useful in the diagnosis. A finding that supports the lack of an association of low ceruloplasmin levels with clinical manifestations of Wilson disease is the observation that asymptomatic patients with successfully treated Wilson disease often have lower levels of ceruloplasmin. In addition, patients with a disorder leading to the absence of ceruloplasmin, hereditary aceruloplasminemia, have tissue deposition of iron but not copper [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Aceruloplasminemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59391355#H59391355\">",
"     \"Tests used in the diagnosis of Wilson disease\", section on 'Serum ceruloplasmin concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impairments in copper transport due to",
"    <em>",
"     ATP7B",
"    </em>",
"    mutation result in excess copper accumulation within hepatocytes. The excess copper is initially bound to metallothionein and distributed evenly throughout the cytoplasm. With progressive copper accumulation, the capacity of metallothionein is exceeded, dense lysosomal copper deposits develop, and hepatocyte injury develops [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of hepatocyte injury from copper is incompletely understood. Both necrosis and apoptosis may be encountered. Cellular injury is mainly due to enhanced free radical production and impaired cellular reducing capacity in the form of lower levels of reduced glutathione, an observation supported by the finding of severe mitochondrial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/24\">",
"     24",
"    </a>",
"    ] and enhanced lipid and DNA oxidative injury, as well as inhibition of protein synthesis by the presence of excess copper in the liver. Hepatocyte apoptosis and hemolytic anemia in Wilson disease have also been linked to copper-induced secretion of acid sphingomyelinase from leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/25\">",
"     25",
"    </a>",
"    ]. Finally, copper excess in liver cells may lead to reduced levels of an inhibitor of apoptosis (X-linked inhibitor of apoptosis), resulting in hepatocyte death.",
"   </p>",
"   <p>",
"    Increased hepatic copper content combined with hepatocyte damage results in the release of copper into the blood, where it binds to albumin or small peptides. This leads to an elevation in free serum copper concentrations (non-ceruloplasmin bound copper), although total serum levels of copper may not be elevated because of the reduced concentration of ceruloplasmin (except in acute liver failure, where massive copper release elevates total serum copper to above twice the normal levels). The increase in free serum copper presumably is the proximate cause of copper deposition and subsequent toxicity in the brain and other tissues. While urinary excretion of copper from this pool of free serum copper increases, it is not able to fully compensate for the decreased biliary excretion, and extra-hepatic tissue copper deposition increases over time, leading to damage of other organs, mainly the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest lesions in Wilson disease are seen in the liver, the site of initial copper accumulation. Early on, there may be steatotic change within hepatocytes, often accompanied by cytoplasmic inclusions within nuclei (glycogenated nuclei), and portal fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef64346 \" href=\"UTD.htm?36/23/37237\">",
"     picture 1",
"    </a>",
"    ). As the disease progresses, frank hepatocellular necrosis occurs, and the histologic lesion may resemble autoimmune chronic hepatitis. There is portal inflammation and fibrosis, piecemeal necrosis with marked swelling and necrosis of periportal hepatocytes, and eventually cirrhosis (",
"    <a class=\"graphic graphic_picture graphicRef53643 \" href=\"UTD.htm?42/56/43909\">",
"     picture 2",
"    </a>",
"    ). Intrahepatic inclusions similar to Mallory bodies may be seen in periportal areas. In acute liver failure due to Wilson disease, apoptotic injury may predominate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/26\">",
"     26",
"    </a>",
"    ]. In this setting, there often is severe hepatocellular dropout occurring on the background of advanced fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic stains for copper (that detect copper binding protein) may demonstrate increased deposits of copper within the liver, renal tubular cells, and brain. The deposition in the liver is initially diffuse and may be hard to see on standard histochemical stains, but with time it becomes more detectable as concentrations of copper and copper binding protein may be seen. Copper histochemical staining may become patchy if cirrhosis is present as concentrations differ between mature tissue and rapidly regenerating nodules. With electron microscopy, striking ultrastructural changes are noted in mitochondria, with dilatation of the tips of the mitochondrial cristae early in the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/29\">",
"     29",
"    </a>",
"    ]. Later, ultrastructural analysis reveals dense lysosomal deposits of copper-metallothionein.",
"   </p>",
"   <p>",
"    Grossly, the brain often is atrophic with increased ventricular size [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13910/abstract/9\">",
"     9",
"    </a>",
"    ]. The putamen and caudate may be brown and shrunken. In advanced disease, there may be cavitation and cyst formation in the putamen and frontal lobes, as well as spongy degeneration of the cerebral cortex and subcortical white matter (particularly in the frontal lobes). Histologic examination of affected areas in the brain demonstrates neuronal loss, pigment- and lipid-containing macrophages, and gliosis. A distinctive feature is the presence of Opalski cells in the globus pallidus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276997922\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wilson disease is an autosomal recessive defect in cellular copper transport, with a prevalence of approximately 1 case in 30,000 live births in most populations. (See",
"      <a class=\"local\" href=\"#H3906210\">",
"       'Genetic defect in Wilson disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H158657485\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wilson disease is caused by a defect in the ATP7B gene that results in a decreased transport of copper from the liver into bile, leading to copper excess in the liver. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excess hepatic copper leads to hepatocyte injury, in part due to enhanced free radical production and oxidative injury to cellular organelles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased hepatic copper content combined with hepatocyte damage results in the release of copper into the blood. The increase in free serum copper (not bound by ceruloplasmin) presumably is the proximate cause of extrahepatic copper deposition and subsequent toxicity in the brain and other tissues. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histochemical staining may reveal copper in the liver, but its absence does not exclude Wilson disease, as there are phases where copper is present but diffuse within the cytoplasm. Copper content is elevated in these cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26676199\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/1\">",
"      Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010; 24:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/2\">",
"      Dedoussis GV, Genschel J, Sialvera TE, et al. Wilson disease: high prevalence in a mountainous area of Crete. Ann Hum Genet 2005; 69:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/3\">",
"      Lau JY, Lai CL, Wu PC, et al. Wilson's disease: 35 years' experience. Q J Med 1990; 75:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/4\">",
"      Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001; 72:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/5\">",
"      Litwin T, Gromadzka G, Czonkowska A. Gender differences in Wilson's disease. J Neurol Sci 2012; 312:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/6\">",
"      Ma J, Betts NM. Zinc and copper intakes and their major food sources for older adults in the 1994-96 continuing survey of food intakes by individuals (CSFII). J Nutr 2000; 130:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/7\">",
"      Cox DW. Genes of the copper pathway. Am J Hum Genet 1995; 56:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/8\">",
"      Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992; 71:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/9\">",
"      Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci 2010; 1184:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/10\">",
"      Cater MA, La Fontaine S, Shield K, et al. ATP7B mediates vesicular sequestration of copper: insight into biliary copper excretion. Gastroenterology 2006; 130:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/11\">",
"      Nagano K, Nakamura K, Urakami KI, et al. Intracellular distribution of the Wilson's disease gene product (ATPase7B) after in vitro and in vivo exogenous expression in hepatocytes from the LEC rat, an animal model of Wilson's disease. Hepatology 1998; 27:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/12\">",
"      Pfeiffer RF. Wilson's Disease. Semin Neurol 2007; 27:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/13\">",
"      Christodoulou J, Danks DM, Sarkar B, et al. Early treatment of Menkes disease with parenteral copper-histidine: long-term follow-up of four treated patients. Am J Med Genet 1998; 76:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/14\">",
"      T&uuml;mer Z, Horn N. Menkes disease: recent advances and new aspects. J Med Genet 1997; 34:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/15\">",
"      Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/16\">",
"      Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/17\">",
"      Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/18\">",
"      Riordan SM, Williams R. The Wilson's disease gene and phenotypic diversity. J Hepatol 2001; 34:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/19\">",
"      Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/20\">",
"      Nanji MS, Nguyen VT, Kawasoe JH, et al. Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 1997; 60:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/21\">",
"      Figus A, Angius A, Loudianos G, et al. Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations. Am J Hum Genet 1995; 57:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/22\">",
"      Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995; 92:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/23\">",
"      Sokol RJ, Twedt D, McKim JM Jr, et al. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology 1994; 107:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/24\">",
"      Gu M, Cooper JM, Butler P, et al. Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet 2000; 356:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/25\">",
"      Lang PA, Schenck M, Nicolay JP, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/26\">",
"      Strand S, Hofmann WJ, Grambihler A, et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 1998; 4:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/27\">",
"      Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008; 48:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/28\">",
"      Johncilla M, Mitchell KA. Pathology of the liver in copper overload. Semin Liver Dis 2011; 31:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13910/abstract/29\">",
"      Sternlieb I. Fraternal concordance of types of abnormal hepatocellular mitochondria in Wilson's disease. Hepatology 1992; 16:728.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3626 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13910=[""].join("\n");
var outline_f13_37_13910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H276997922\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158657485\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3905564\">",
"      COPPER METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3906210\">",
"      GENETIC DEFECT IN WILSON DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276997922\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26676199\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3626\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3626|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/23/37237\" title=\"picture 1\">",
"      Early liver biopsy Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/56/43909\" title=\"picture 2\">",
"      Wilson disease simulating AIH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13911="Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults";
var content_f13_37_13911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Paul Cornia, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Benjamin Lipsky, MD, FACP, FIDSA, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13911/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/37/13911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19936873\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertussis, also known as &ldquo;whooping cough,&rdquo; is a highly contagious, acute respiratory illness caused by Bordetella pertussis. In the pre-vaccine era, the disease predominantly affected children &lt;10 years of age and usually manifested as a prolonged cough illness with one or more of the classical symptoms, including inspiratory whoop, paroxysmal cough, and post-tussive emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the introduction of pertussis vaccines, the epidemiology of reported pertussis infections has changed; in the United States in the 1990s, more than one-half of cases occurred in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/2\">",
"     2",
"    </a>",
"    ]. Infected adolescents and adults serve as a reservoir for infection of infants and children in whom serious morbidity and mortality may occur. Symptoms and signs in adolescents and adults are often non-specific and the diagnosis may not be considered.",
"   </p>",
"   <p>",
"    Clinical manifestations and diagnosis of pertussis will be reviewed here. Issues related to the pathogenesis, epidemiology, treatment, and prevention of pertussis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746150\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period is typically 7 to 10 days following exposure, but may be three weeks or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/3\">",
"     3",
"    </a>",
"    ]. This incubation period is considerably longer than that of common upper respiratory infections, such as the common cold (one to three days). Infection with B. pertussis in individuals without immunity is characterized by three phases: the catarrhal phase, the paroxysmal phase and the convalescent phase. In adolescents or adults with history of prior infection or vaccine-induced immunity, classic symptoms may or may not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19936977\">",
"    <span class=\"h2\">",
"     Catarrhal phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catarrhal phase is the earliest phase of illness; it lasts one to two weeks and is characterized by non-specific symptoms including generalized malaise, rhinorrhea, and mild cough; mild temperature elevations may be present, but high fever is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/4\">",
"     4",
"    </a>",
"    ]. Two early clinical findings suggestive of pertussis are excessive lacrimation and conjunctival injection. Diagnostic tests are most accurate during this phase even though clinical manifestations may be nonspecific. (See",
"    <a class=\"local\" href=\"#H5005306\">",
"     'Approach to diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746164\">",
"    <span class=\"h2\">",
"     Paroxysmal phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paroxysmal stage begins during the second week of illness. The hallmark symptom, paroxysmal cough, is a series of severe, vigorous coughs that occur during a single expiration. Paroxysms often occur in groups and can be quite distressing, particularly to parents of an affected child. Vigorous inspiration causes the distinctive &lsquo;whooping&rsquo; sound. This sound is more likely to be observed among infants and small children due to the relatively small caliber of the trachea. Post-tussive syncope or emesis can also occur during the paroxysmal phase.",
"   </p>",
"   <p>",
"    Cough may be precipitated by acts such as yawning, stretching, laughing, yelling, or exercise; it may also be worse at night and can be triggered by the inhalation of steam, mist, or other respiratory irritants. Patients often feel well and have few symptoms between cough paroxysms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/4\">",
"     4",
"    </a>",
"    ]. Untreated, the paroxysmal phase generally lasts two to three months, then gradually transitions to the convalescent phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5001888\">",
"    <span class=\"h2\">",
"     Convalescent phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The convalescent phase is characterized by a gradual reduction in the frequency and severity of cough. It usually lasts one to two weeks, but may be prolonged. The total duration of all three phases is often about three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746178\">",
"    <span class=\"h2\">",
"     Adolescents and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of pertussis in adolescents and adults are often less severe than in infants and children. Prior infection or immunization may attenuate the illness, but neither confers lifelong immunity. As a result, prolonged cough may be the only symptom in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/5\">",
"     5",
"    </a>",
"    ]. The presence or absence of classically described manifestations (ie, inspiratory whoop, paroxysmal cough, post-tussive emesis, or syncope) is only modestly useful to determine whether prolonged cough represents pertussis in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/6\">",
"     6",
"    </a>",
"    ]. Other symptoms, such as sputum production, coryza, sweating episodes, and sore throat may also occur.",
"   </p>",
"   <p>",
"    Several studies have shown that pertussis is responsible for a substantial portion of prolonged cough illnesses in adolescents and adults; in one report of adults with a cough lasting more than one week, pertussis was found to be the cause in 13 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746185\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of pertussis may be related to the infection itself (eg, pneumonia, otitis media) or the mechanical sequelae of the severe cough (eg, subconjunctival hemorrhage, hernia, rib fractures, urinary incontinence or lumbar strain). Rarely, more serious problems caused by vigorous coughing include intracranial hemorrhage, stroke due to carotid or vertebral artery dissection, and encephalopathy or seizures (presumed due to hypoxia). &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In general, morbidity and mortality due to pertussis are most common in infants and young children. In adolescents and adults, the prolonged cough may result in substantial time lost from school or work [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/8\">",
"     8",
"    </a>",
"    ], as well as social isolation, sleep deprivation, or anxiety about an undiagnosed condition. Asthma and smoking increase the severity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746192\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cough is broad; the duration of illness is useful in narrowing the potential causes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/9\">",
"     9",
"    </a>",
"    ]. Cough that has been present less than three weeks is considered acute, cough present for three to eight weeks is classified as subacute, and cough present for more than eight weeks is chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/10\">",
"     10",
"    </a>",
"    ]. Many adolescents and adults with pertussis, particularly those with milder manifestations, first seek medical attention only after several weeks of coughing (ie, with a subacute or chronic cough illness). &nbsp;",
"   </p>",
"   <p>",
"    The most common cause of acute cough is self-limited, viral upper respiratory tract infections (eg, the common cold). Subacute cough often represents persistence of an acute respiratory infection (eg, viral or bacterial upper airway infections or lower respiratory tract infections, such as pneumonia). Chronic cough may be attributable to cigarette smoking, gastroesophageal reflux disease, asthma, post-nasal drip, and angiotensin converting enzyme inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746199\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosing pertussis in adolescent and adults requires a high index of suspicion. Early diagnosis is important as it can prevent the spread of infection, particularly in vulnerable populations (eg, infants and young children). In addition, antibiotic treatment may shorten the duration of symptoms. Microbiological testing is needed given the variable and non-specific symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5005306\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical case definition advocated by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) is a cough illness lasting two weeks without an apparent cause, with one of the following symptoms: paroxysms of coughing, inspiratory whoop or post-tussive emesis (",
"    <a class=\"graphic graphic_table graphicRef80177 \" href=\"UTD.htm?41/54/42859\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In the setting of an outbreak or known close contact to a confirmed case of pertussis, the presence of a cough lasting &ge;2 weeks is sufficient for clinical diagnosis (in the absence of other symptoms). In outbreaks, the sensitivity and specificity of this case definition for detecting culture-positive pertussis have been 84 and 63 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In non-outbreak settings, the choice of diagnostic test (culture, polymerase chain reaction [PCR], serology) depends upon the duration of cough (",
"    <a class=\"graphic graphic_figure graphicRef83305 \" href=\"UTD.htm?0/24/397\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with less than two weeks of cough in whom there is clinical concern for pertussis, perform both culture and PCR. The sensitivity of culture is highest during the first two weeks of illness.",
"     </li>",
"     <li>",
"      For patients with two to four weeks of cough, perform both culture and PCR. The sensitivity of culture declines after the first two weeks, but PCR remains useful up to four weeks since it can detect non-viable organisms. Both tests should be performed since the accuracy of PCR as a stand-alone diagnostic test requires further study. Serology may be a useful alternative to culture in this setting once it has been standardized and rigorously tested in the non-outbreak, community setting.",
"     </li>",
"     <li>",
"      For patients with more than four weeks of cough, only serology is useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with discordant test results (eg, positive culture with negative PCR, negative culture with positive PCR, or positive serology with negative PCR) should be presumed to have pertussis.",
"   </p>",
"   <p>",
"    Confirmed cases of pertussis are defined as follows (",
"    <a class=\"graphic graphic_table graphicRef80177 \" href=\"UTD.htm?41/54/42859\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with an acute cough illness of any duration and culture positive from nasopharyngeal secretions",
"     </li>",
"     <li>",
"      Patients who meet the clinical case definition with laboratory confirmation by polymerase chain reaction (PCR) from nasopharyngeal secretions",
"     </li>",
"     <li>",
"      Patients who meet the clinical case definition and are epidemiologically linked to a case confirmed by either culture or PCR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Confirmed cases should be reported to local public health authorities. Probable",
"    <em>",
"    </em>",
"    cases are defined as patients that meet the clinical case definition but without laboratory confirmation or epidemiological link to a laboratory-confirmed case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746213\">",
"    <span class=\"h2\">",
"     Laboratory tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbiological confirmation is needed to establish the diagnosis of B. pertussis infection, as well as for public health surveillance and for outbreak investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. Bacterial culture and PCR are the most useful clinical tools, and these are the modalities recommended by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specimens must be collected by swab or aspiration from the ciliated respiratory epithelium of the posterior nasopharynx where B. pertussis resides, not the anterior nares or throat (",
"    <a class=\"graphic graphic_picture graphicRef81502 \" href=\"UTD.htm?21/0/21505\">",
"     picture 1",
"    </a>",
"    ). Aspiration is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/19\">",
"     19",
"    </a>",
"    ], although supplies to perform this technique are often not readily available. Cotton or rayon swabs should",
"    <strong>",
"     not",
"    </strong>",
"    be used for obtaining culture specimens as they contain fatty acids that are toxic to B. pertussis. Instead, use a calcium alginate or Dacron swab with a flexible metal shaft. Because calcium alginate may interfere with PCR assays, Dacron swabs may be optimal. Face mask and gloves should be worn.",
"   </p>",
"   <p>",
"    Obtaining a specimen from the posterior nasopharynx is uncomfortable for the patient and suboptimal specimen collection is common. Therefore, the patient should be educated about the importance of a properly obtained specimen and forewarned about the discomfort of the procedure. Proper specimen collection will typically induce cough or sneeze.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746220\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture is the standard for diagnosis; it has excellent specificity (100 percent), but sensitivity in clinical practice is only 30 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/20\">",
"     20",
"    </a>",
"    ]. Factors that reduce the sensitivity of culture include the fastidious nature of the organism, prolonged duration of illness by the time a specimen is collected, recent antibiotic use, prolonged transport time to the laboratory and delayed specimen plating [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/4\">",
"     4",
"    </a>",
"    ]. Immediate plating of the specimen is optimal, but not typically practical in clinical situations.",
"   </p>",
"   <p>",
"    After specimen collection, use of a special transport media (Regan-Lowe agar) rather than standard media (such as modified Stuart&rsquo;s) will help to prevent loss of B. pertussis and overgrowth of other nasopharyngeal organisms. Borget-Genou agar is the classic medium for isolating B. pertussis; Regan-Lowe agar is preferred by most laboratories because of its longer shelf life. Growth on culture media typically takes 7 to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746234\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR testing may detect small numbers of viable and non-viable organisms, thereby increasing sensitivity; specificity is high. Primers from four chromosomal regions are employed: repeated insertion sequences (such as IS481, also present in lesser quantities in",
"    <em>",
"     Bordetella holmesii",
"    </em>",
"    and",
"    <em>",
"     Bordetella bronchiseptica",
"    </em>",
"    ), the pertussis toxin gene (PT), the PT promoter region, and the adenylate cyclase gene (not specific to B. pertussis) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR is not affected by previous antibiotic use and results are typically available within one to two days. Compared with culture, PCR may increase the diagnostic yield three to five fold [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Disadvantages to PCR include its relatively high cost and lack of availability to many clinicians, as well as the potential for false-positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/24\">",
"     24",
"    </a>",
"    ]. There are no standardized protocols, reagents or reporting formats. The CDC recommends use of PCR together with culture for diagnostic of pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746241\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is used for epidemiologic or research purposes, but it is not widely available and is hampered by lack of standardization.",
"   </p>",
"   <p>",
"    Natural infection with B. pertussis results in production of IgA, IgG, and IgM antibodies to a variety of antigens; primary immunization induces mainly IgG and IgM antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/17\">",
"     17",
"    </a>",
"    ]. Serologic testing typically involves comparing levels of pertussis antibodies (IgA or IgG to PT, filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae, or sonicated whole organism) in acute and convalescent (more than four weeks after the acute sample is obtained) sera; a substantial change in the titers (typically a fourfold increase or more) suggests infection. Infection with other Bordetella species also induces antibodies to FHA, PRN, and the sonicated whole organism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/26\">",
"     26",
"    </a>",
"    ] and FHA antibodies are also induced by other bacteria (eg, H. influenzae, M. pneumoniae, and C. pneumoniae) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/27\">",
"     27",
"    </a>",
"    ], so these are not specific for B. pertussis. IgA and IgG antibodies to PT are most specific for the diagnosis of B. pertussis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A practical problem with serologic testing is the timing of obtaining the acute phase specimen. In the setting of delayed collection of the acute phase specimen, antibody titers may have already peaked and a further rise in the convalescent specimen may not be observed. Alternatively, a single sample titer above a designated threshold (typically IgG anti-PT &ge;100-125",
"    <span class=\"nowrap\">",
"     EU/mL)",
"    </span>",
"    or decreases in antibody titers between the acute and convalescent titers may be diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/28\">",
"     28",
"    </a>",
"    ]. Single specimen titers are useful in adolescent and adults but not in children since recent immunization can affect the results. However, because the acellular pertussis vaccine contains pertussis toxin (PT), recent booster vaccination does also affect serologic testing results in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5004721\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct fluorescent antibody (DFA) testing is inexpensive and provides rapid results, but has poor sensitivity and specificity so is not recommended.",
"   </p>",
"   <p>",
"    Pulsed-field gel electrophoresis (PFGE) is a DNA fingerprinting technique that may be useful for epidemiological purposes (eg, community or nosocomial outbreaks) but the availability is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13911/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248746262\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pertussis is highly contagious. The incubation period is typically approximately one week, but may be three weeks or longer. Pertussis infection in individuals without immunity is characterized by three phases: the catarrhal phase, the paroxysmal phase, and the convalescent phase. (See",
"      <a class=\"local\" href=\"#H248746150\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adolescents or adults with history of prior infection or vaccine-induced immunity, classic manifestations may or may not occur. The only symptom may be prolonged cough. (See",
"      <a class=\"local\" href=\"#H248746178\">",
"       'Adolescents and adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical case definition advocated by the United States Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) is a cough illness lasting two weeks without clear cause, and one of the following symptoms: paroxysms of coughing, inspiratory whoop or post-tussive emesis (",
"      <a class=\"graphic graphic_table graphicRef80177 \" href=\"UTD.htm?41/54/42859\">",
"       table 1",
"      </a>",
"      ). In the setting of an outbreak or known close contact to a confirmed case of pertussis, the presence of a cough lasting &ge;2 weeks is sufficient for clinical diagnosis (in the absence of other symptoms). (See",
"      <a class=\"local\" href=\"#H5005306\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of diagnostic test (culture, polymerase chain reaction [PCR], serology) depends upon the duration of cough. Culture and PCR are appropriate for patients with up to four weeks of cough; the sensitivity of culture is highest during the first two weeks of illness. For patients with more than four weeks of cough, only serology is useful but the lack of a widely available, standardized test limits its use (",
"      <a class=\"graphic graphic_figure graphicRef83305 \" href=\"UTD.htm?0/24/397\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5005306\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirmed cases of pertussis are defined as: (1) patients with an acute cough illness of any duration and positive culture from nasopharyngeal secretions, (2) patients who meet the clinical case definition with laboratory confirmation by PCR from nasopharyngeal secretions, or (3) patients who meet the clinical case definition and are epidemiologically linked to a case confirmed by culture or PCR (",
"      <a class=\"graphic graphic_table graphicRef80177 \" href=\"UTD.htm?41/54/42859\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5005306\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H248747105\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Christopher Ohl, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/1\">",
"      G&uuml;ri D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/3\">",
"      Heininger U, Cherry JD, Stehr K, et al. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics 1998; 102:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/4\">",
"      Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/5\">",
"      Couzigou C, Flahault A. Is pertussis being considered as a cause of persistent cough among adults? Eur J Epidemiol 2003; 18:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/6\">",
"      Cornia PB, Hersh AL, Lipsky BA, et al. Does this coughing adolescent or adult patient have pertussis? JAMA 2010; 304:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/7\">",
"      Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/8\">",
"      De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/9\">",
"      Pratter MR, Brightling CE, Boulet LP, Irwin RS. An empiric integrative approach to the management of cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:222S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/10\">",
"      Pratter MR. Cough and the common cold: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:72S.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Surveillance &amp; Reporting. file://www.cdc.gov/pertussis/surv-reporting.html.",
"    </li>",
"    <li>",
"     World Health Organization. WHO-recommended surveillance standard of pertussis. file://www.who.int/immunization_monitoring/diseases/pertussis_surveillance/en/index.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/13\">",
"      Patriarca PA, Biellik RJ, Sanden G, et al. Sensitivity and specificity of clinical case definitions for pertussis. Am J Public Health 1988; 78:833.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Diagnosis Confirmation. file://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/15\">",
"      Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/16\">",
"      von K&ouml;nig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/17\">",
"      Cherry JD, Grimprel E, Guiso N, et al. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 2005; 24:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/18\">",
"      Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease control and Prevention. Guidelines for the Control of Pertussis Outbreaks. CDC: Atlanta, GA, 2000. file://www.cdc.gov/vaccines/pubs/pertussis-guide/guide.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/20\">",
"      Young S, Anderson G, Mitchell P. Laboratory observations during an outreak of pertussis. Clinical Microbiology Newsletter 1987; 9:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/21\">",
"      M&uuml;ller FM, Hoppe JE, Wirsing von K&ouml;nig CH. Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol 1997; 35:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/22\">",
"      Schl&auml;pfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis J 1995; 14:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/23\">",
"      Schmidt-Schl&auml;pfer G, Liese JG, Porter F, et al. Polymerase chain reaction (PCR) compared with conventional identification in culture for detection of Bordetella pertussis in 7153 children. Clin Microbiol Infect 1997; 3:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/24\">",
"      Lievano FA, Reynolds MA, Waring AL, et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 2002; 40:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/25\">",
"      Fry NK, Tzivra O, Li YT, et al. Laboratory diagnosis of pertussis infections: the role of PCR and serology. J Med Microbiol 2004; 53:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/26\">",
"      Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/27\">",
"      Vincent JM, Cherry JD, Nauschuetz WF, et al. Prolonged afebrile nonproductive cough illnesses in American soldiers in Korea: a serological search for causation. Clin Infect Dis 2000; 30:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/28\">",
"      Simondon F, Iteman I, Preziosi MP, et al. Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 1998; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/29\">",
"      Guiso N, Berbers G, Fry NK, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011; 30:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/30\">",
"      Bisgard KM, Christie CD, Reising SF, et al. Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. J Infect Dis 2001; 183:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/31\">",
"      Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis studies. J Infect Dis 2000; 181:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13911/abstract/32\">",
"      Nouvellon M, Gehanno JF, Pestel-Caron M, et al. Usefulness of pulsed-field gel electrophoresis in assessing nosocomial transmission of pertussis. Infect Control Hosp Epidemiol 1999; 20:758.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8045 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13911=[""].join("\n");
var outline_f13_37_13911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H248746262\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19936873\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H248746150\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19936977\">",
"      Catarrhal phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248746164\">",
"      Paroxysmal phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5001888\">",
"      Convalescent phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248746178\">",
"      Adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H248746185\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H248746192\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H248746199\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5005306\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H248746213\">",
"      Laboratory tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H248746220\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H248746234\">",
"      - Polymerase chain reaction testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H248746241\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5004721\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H248746262\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H248747105\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8045|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/24/397\" title=\"figure 1\">",
"      Timeline for diagnosis of pertussis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8045|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/0/21505\" title=\"picture 1\">",
"      Nasopharyngeal swab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8045|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/54/42859\" title=\"table 1\">",
"      Pertussis CDC case definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13912="Xenotransplantation and the kidney";
var content_f13_37_13912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Xenotransplantation and the kidney",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13912/contributors\">",
"     Jeffrey L Platt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13912/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13912/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13912/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/37/13912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transplantation of cells, tissues, and organs between individuals of different species is referred to as xenotransplantation. The clinical application of xenotransplantation has been a goal of transplant physicians since the beginning of the twentieth century. At that time, the kidneys of animals were used during early clinical transplantation because it was not readily apparent how human kidneys could be ethically retrieved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The shortage of human kidneys for transplantation is currently severe, resulting in a significant waiting time for any allograft. Other approaches to organ replacement, such as implantable devices, cell or stem cell therapies and organogenesis are sometimes considered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/2\">",
"     2",
"    </a>",
"    ]; however, one, and perhaps the most realistic, possibility is xenotransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The use of animals as a source of transplants would eliminate this fundamental problem of clinical transplantation. Additional benefits may include the ability to prevent the recurrence of some infectious diseases (as animal organs are not susceptible to certain viruses such as hepatitis B and C) and the ability to introduce extrinsic genetic material for therapeutic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these possible benefits, xenotransplantation is a field of great controversy. This stems in part from difficulty in overcoming the immune hurdles to xenografting and, in part, from the theoretical possibility that a xenograft may pose risks to public health by the introduction of infectious agents. A review of xenotransplantation is presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF XENOGRAFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most obvious animal to use as a source of xenografts is one that is genetically close to humans, such as the chimpanzee. In the early 1960s, a series of transplants of chimpanzee kidneys into patients with renal failure were performed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/6\">",
"     6",
"    </a>",
"    ]. These transplants functioned for up to nine months; in some cases, the cause of transplant failure and patient death was intercurrent disease and not rejection.",
"   </p>",
"   <p>",
"    More recently, baboon livers functioned for months after transplantation into two patients with hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/7\">",
"     7",
"    </a>",
"    ]. As with some of the chimpanzee kidney transplants, intercurrent illness rather than intrinsic failure of the livers resulted in patient death.",
"   </p>",
"   <p>",
"    Although xenografts of chimpanzee kidneys appear successful, most investigators currently avoid the use of non-human primates as a source of xenografts because non-human primates are scarce and may harbor deadly viruses. Instead, non-primates, particularly the pig, are preferred because they are available in unlimited numbers. Additional benefits are that porcine kidneys are appropriately sized for humans and have only a limited risk of transferring infectious agents (as discussed below).",
"   </p>",
"   <p>",
"    Using technologies described below, swine kidneys have survived as long as three months and swine hearts as long as six months in non-human primates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/8\">",
"     8",
"    </a>",
"    ]. Swine tissues, such as islets and hepatocytes, have functioned months longer; still, further advances are needed to make these transplants clinically feasible.",
"   </p>",
"   <p>",
"    Xenotransplantation might also be used to generate functioning kidneys. With this strategy, animal cells committed to a renal lineage, particularly metanephroi, are isolated and transplanted into an appropriate recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Limited studies suggest that developing metanephroi surgically placed into the omentum of cross-species hosts (eg, pig to rodent) differentiate, grow, become vascularized, and exhibit excretory behavior.",
"   </p>",
"   <p>",
"    In a still more advanced strategy, human stem cells might be generated from the cells of a person needing treatment and grown into renal primordia in an animal host [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The human renal primordial cells could be harvested and transferred back to the person from whom the stem cells were generated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BARRIERS TO XENOTRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant hurdles to the successful application of xenotransplantation. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunological responses of the recipient against the graft",
"     </li>",
"     <li>",
"      Physiological limitations of the graft",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Ethical considerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the following section addresses kidney xenotransplantation, this discussion also largely applies to cardiac, liver, and lung xenotransplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunologic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without genetic manipulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe immune modulation, a pig organ transplanted into a human would succumb because of the following reactions (",
"    <a class=\"graphic graphic_algorithm graphicRef76845 \" href=\"UTD.htm?15/59/16317\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hyperacute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperacute rejection may arise in transplanted organs, whether human to human or across species. It is not observed with transplanted tissue or cells, such as pancreatic islets or hepatocytes. This severe reaction may occur within minutes to hours, and would be observed in many, if not most, pig kidneys transplanted into unmodified human patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperacute rejection is characterized by the aggregation of platelets, formation of platelet thrombi, and the presence of interstitial hemorrhage in the recently transplanted organ. The dissolution of graft blood vessels and accumulation of neutrophils is sometimes, but not invariably, observed.",
"   </p>",
"   <p>",
"    Hyperacute rejection of pig organs by primates is triggered by the binding to endothelium of \"xenoreactive natural antibodies.\" These antibodies predominately recognize Gal alpha1-3Gal, a sugar expressed by lower mammals such as pigs but not by humans, apes, or Old World Monkeys. The anti-Gal alpha1-3Gal antibodies are believed to be similar to the isohemagglutinins that recognize blood groups A and B [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binding of xenoreactive natural antibodies to the xenograft endothelium triggers activation of the complement cascade, with activated complement mediating the rejection reaction. Xenografts appear to be particularly susceptible to complement-mediated injury because porcine complement regulatory proteins fail to dampen the activation of human complement on xenogeneic cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most evidence suggests that hyperacute rejection is caused by the accumulation of terminal complement complexes (C5b-9) on endothelial surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/15\">",
"     15",
"    </a>",
"    ]. Deposition of terminal complement complexes causes an alteration in the shape of endothelium, which brings platelets into contact with underlying matrix, thereby triggering aggregation and thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hyperacute rejection is arguably the most severe of all known immune responses, it can be prevented by one or more of the following strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depleting xenoreactive antibodies from the recipient's circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibiting complement activation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/20\">",
"       20",
"      </a>",
"      ]. This can be achieved by the administration of cobra venom factor (which depletes C3), soluble complement receptor type 1 (which inhibits the critical convertase enzymes of the complement cascade [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/21\">",
"       21",
"      </a>",
"      ]), or anti-C5 antibodies (which inhibit the assembly of terminal complement complexes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/22\">",
"       22",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Expressing the human complement regulatory proteins, decay accelerating factor (hCD55) or membrane cofactor protein (hCD46), in the animal organ [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/23\">",
"       23",
"      </a>",
"      ]. Expression of these proteins can be achieved by making transgenic animals in which the genes for the human proteins are integrated into the porcine genome [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/24\">",
"       24",
"      </a>",
"      ]. The use of transgenic organs as a means of preventing hyperacute rejection was first described by the author [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/25\">",
"       25",
"      </a>",
"      ] and the application to the kidney was first described by Cozzi [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/26\">",
"       26",
"      </a>",
"      ]. In both of these studies and in many subsequently published, transgenic porcine organs transplanted into baboons continued to function without evidence of structural damage well beyond the period when hyperacute rejection usually occurs (24 hours). Protection may be further enhanced with a triple transgenic animal that expresses hCD46, hCD55, and hCD59 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eradicating Gal(alpha)1-3Gal by knocking out (alpha)1,3 galactosyltransferase, the enzyme that catalyzes synthesis of that sugar, in cloned pigs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/28-32\">",
"       28-32",
"      </a>",
"      ]. The transplantation of such kidneys into baboons has allowed the survival of renal xenografts of up to several months [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute vascular rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also known as antibody-mediated rejection, acute vascular rejection invariably occurs if hyperacute rejection is averted. Acute vascular rejection is currently recognized as the major hurdle to clinical application of xenotransplantation. As with acute vascular rejection of allografts, acute vascular rejection of xenografts is characterized by severe endothelial thickening, injury, ischemia, and thrombosis, with thrombi consisting of fibrin as well as platelets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a variety of factors have been implicated, acute vascular rejection is triggered by antibodies directed against the graft blood vessels. Thus, depletion of xenoreactive antibodies from xenograft recipients or suppression of antibody synthesis by immunosuppressive agents can avert or delay the occurrence of acute vascular rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some antibodies that cause acute vascular rejection are specific for Gal alpha1-3Gal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/23,35\">",
"     23,35",
"    </a>",
"    ]. However, other antibodies such as those directed against major histocompatibility antigen and other components of endothelium can cause this process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention &mdash; Although acute vascular rejection has been prevented in a few cases of pig-to-primate xenotransplantation, it remains a major therapeutic challenge. Among the approaches to preventing acute vascular rejection are the induction of accommodation, the induction of immunological tolerance, and the genetic engineering of xenograft sources to lower antigen expression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Accomodation",
"      </strong>",
"      &mdash; When antibodies against a kidney transplant donor are removed from the circulation or temporarily prevented from causing the demise of the graft, the graft may undergo a process known as accommodation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/24\">",
"       24",
"      </a>",
"      ]. This was first described clinically in blood group O recipients of blood group A and B donor kidneys [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/36\">",
"       36",
"      </a>",
"      ]. However, it is best characterized in xenografts [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accommodation is sometimes associated with expression in the transplant of \"protective\" genes, such as heme oxygenase-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/39\">",
"     39",
"    </a>",
"    ]. These genes inhibit the cellular machinery from contributing to injury caused by exogenous substances. Accommodation may represent a broader phenomenon in which the kidney and other organs exposed to noxious substances or cytokines acquire resistance to ongoing injury by expressing such substances or cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/37,40\">",
"     37,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether accommodation can be achieved with sufficient regularity to allow xenotransplantation to occur is uncertain. However, as mentioned, it is clearly feasible in allotransplants performed across ABO barriers, which is a setting analogous to the presence of antibodies directed against Gal alpha1-3Gal.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Tolerance",
"      </strong>",
"      &mdash; A second approach to preventing acute vascular rejection is the induction of immunological tolerance, which is defined as specific nonresponsiveness to a foreign antigen or tissue. In general, immunological tolerance is the goal of all clinical transplantation. Because of the severe immune responses that would otherwise be uncontrollable, some investigators suggest that the successful application of xenotransplantation will ultimately depend upon the induction of tolerance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the most promising approaches to inducing tolerance for xenotransplantation is the transplantation of donor bone marrow into recipients whose ability to mount acute immune responses is suppressed or eradicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Another possible approach is to inhibit \"co-stimulation,\" leading to the inactivation of B cells and T cells. Which of these or other approaches may work between highly disparate species is still unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Genetic engineering",
"      </strong>",
"      &mdash; A third strategy to prevent acute vascular rejection is to genetically engineer the animal source so that the relevant antigens are not expressed. The ability to clone pigs makes such gene targeting possible. The (alpha)1,3galactosyltransferase gene was targeted in cloned pigs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. If the relevant antigen is Gal alpha1-3Gal, other approaches may be used to suppress its expression [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reports indicate that kidneys from (alpha)1,3galactosyltransferase knockout pigs still undergo acute vascular rejection, due presumably to antibodies against antigens other than (alpha)1,3galactosyltransferase. Thus, genetic engineering to lower specific antigen expression may be impractical.",
"   </p>",
"   <p>",
"    Nevertheless, additional genes may be introduced into the donor animal that would confer resistance to rejection. One such possibility is the overexpression of anticoagulants, such as hirudin, which was shown to completely inhibit acute humoral rejection in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cellular rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xenografts, like allografts, are susceptible to cellular rejection. Critical questions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether the cellular rejection of xenografts resembles the cellular rejection of allografts [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/47\">",
"       47",
"      </a>",
"      ]. This is under active investigation.",
"     </li>",
"     <li>",
"      Whether the process can be controlled by immunosuppressive therapies. Immunosuppression used for allotransplant rejection appears to prevent the cellular rejection of xenotransplants over a period of weeks to months [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/48\">",
"       48",
"      </a>",
"      ], and the production of large quantities of antibodies against antigens other than Gal alpha1-3Gal [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/49\">",
"       49",
"      </a>",
"      ]. Despite this, some argue that the cellular immune responses to xenotransplantation may be so severe that tolerance will also be needed [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chronic rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bane of allotransplantation is chronic rejection, a disorder that is also likely to undermine successful xenotransplantation. However, with xenotransplantation but unlike allotransplantation, it is possible to replace a chronically rejected organ with another readily available xenotransplant.",
"   </p>",
"   <p>",
"    The cause and treatment of chronic rejection of allografts is unclear. Among the possible causes of chronic rejection of experimental allografts and xenografts are antibodies directed against the transplanted organ [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/50\">",
"     50",
"    </a>",
"    ]. To the extent that such antibodies contribute to the rejection of clinical xenografts, the approaches discussed above for acute vascular rejection might also be applied to chronic rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physiologic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main clinical imperative of xenotransplantation is the functional replacement of a failing organ or organ system. Thus, the function of the clinical xenograft is a preeminent issue.",
"   </p>",
"   <p>",
"    It is unlikely that an organ xenograft, particularly a kidney xenograft, will function exactly like an allograft. Preliminary studies reveal, however, that transplanted pig kidneys can maintain normal electrolyte, acid-base, calcium, and phosphorus balance, and blood pressure in baboons. Some report that monkeys and baboons with renal xenografts have hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. It is unclear, however, whether this complication reflects the limited capabilities of the transplanted kidneys or the complications of immunosuppressive therapy given in higher than normal doses.",
"   </p>",
"   <p>",
"    Monkeys with renal xenografts also may develop a significant non-hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/52\">",
"     52",
"    </a>",
"    ]. The administration of erythropoietin returns the hemoglobin concentration to near normal levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of transferring an infectious agent from the xenotransplant to the recipient or community is one of the major hurdles to the clinical application of xenotransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Agents that cause pyogenic infections and influenza are among those that could infect a human if they were carried with a xenograft. However, nearly all (if not all) agents that are infectious for the pig can be excluded from potential xenograft donors by rigorous approaches to animal raising and isolation. In this way, a xenograft would probably be a less likely source of infection than a human allograft.",
"   </p>",
"   <p>",
"    What cannot be excluded by these approaches are organisms that are endogenous to the porcine genome, such as endogenous retroviruses. The genome of all species contains retro-elements and some have retroviruses capable of replicating and infecting.",
"   </p>",
"   <p>",
"    The pig has a retrovirus known as porcine endogenous retrovirus (PERV), which is capable of infecting human cells in culture and murine cells in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Studies of human subjects to this point have failed to demonstrate that this virus can infect human cells in vivo, cause disease, or be transferred from one individual to another [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/56\">",
"     56",
"    </a>",
"    ]; however, PERV is capable of infecting human cells that may fuse spontaneously with swine cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various reasons for the limited infectivity of PERV have been hypothesized, including natural resistance of the human host [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/58\">",
"     58",
"    </a>",
"    ]. In this author's judgment, clinical trials are required to determine whether this agent poses any risk for humans.",
"   </p>",
"   <p>",
"    Additional potential human pathogens include herpesviruses, particularly porcine cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/54\">",
"     54",
"    </a>",
"    ]. Tissue invasive disease due to this organism has been described in pig to primate xenotransplant models. Porcine cytomegalovirus, however, can be excluded from swine herds by early weaning of newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ethical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ethical aspects of xenotransplantation have been considered by various agencies, such as the Institute of Medicine in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/59\">",
"     59",
"    </a>",
"    ] and the Nuffield Council in Great Britain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/60\">",
"     60",
"    </a>",
"    ] and International Xenotransplantation Association [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/61\">",
"     61",
"    </a>",
"    ]. Although there are some individuals who oppose any use of animals for purposes such as xenotransplantation, these and other agencies have concluded that such opposition should not be public policy in societies that allow the use of animals as a source of food.",
"   </p>",
"   <p>",
"    Of greater concern is the possibility that a xenograft may carry an infectious agent to the xenograft recipient and more broadly into society, thereby making the xenograft potentially a matter of public health. As indicated previously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/4\">",
"     4",
"    </a>",
"    ], there is no evidence that a porcine xenograft may carry novel infectious agents into the human population that would not arrive in humans through animal husbandry, slaughterhouses, and other agricultural activities unrelated to transplantation.",
"   </p>",
"   <p>",
"    One potential exception is the porcine endogenous retrovirus, which apparently has not entered human populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/61\">",
"     61",
"    </a>",
"    ]. However, there is no evidence that PERV can infect or spread among humans as a result of xenotransplantation or other types of exposure to pigs. Nevertheless, because there remains concern about this issue, agencies in various countries have formulated public policies for the regulation of xenotransplantation and the screening and evaluation of recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSSIBLE FUTURE INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the biological hurdles to renal xenotransplantation are overcome, the next critical question is which patients with renal disease would be most suitable to receive xenotransplants. This is particularly challenging because renal transplantation, unlike the transplantation of other organs, is not necessarily life-saving because dialysis is readily available in most countries. On the other hand, xenotransplantation might be especially appealing as the cost could eventually be lower than that in other procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, xenotransplantation might be preferred in certain medical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Presensitized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xenotransplants may be initially considered for a limited number of individuals who are presensitized to multiple potential donors and are therefore less likely to receive an allograft. In this setting, the successful performance of xenotransplants assumes that anti-HLA antibodies do not cross-react with porcine major histocompatibility antigens (SLA) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal xenotransplants may be appropriate for young infants with kidney failure in whom dialysis is very difficult to perform. Such infants are also difficult to transplant because of the mismatch in size between the adult kidney and the infant. A xenograft could be used in selected cases to allow the infant to grow to a size that is more optimal for allotransplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=see_link\">",
"     \"General principles of kidney transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hyperoxaluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary hyperoxaluria may be suitable candidates because conventional transplant experience in these patients has been relatively disappointing. Renal oxalosis leading to loss of the graft occurs in many patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=see_link\">",
"     \"Complications of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-positive patients with renal failure may be candidates for xenotransplantation, since many transplant centers exclude such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .) However, given the long-term survival of some HIV-positive patients with current therapy, a network of centers in the United States has been created where the feasibility of transplanting these patients is being evaluated in a systematic manner. Other transplant programs are considering the transplantation of HIV patients on an individual basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link\">",
"     \"Solid organ transplantation in HIV-infected individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FUTURE APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xenotransplantation may enter the clinic in a stepwise fashion. In the past:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Porcine livers have been used as devices for the treatment of fulminant hepatic failure.",
"     </li>",
"     <li>",
"      Porcine skin has been used for the treatment of burns.",
"     </li>",
"     <li>",
"      Porcine cells have been transplanted into patients with Parkinson's disease and unremitting pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Soon, the transplantation of porcine hepatocytes and islet cells may be undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13912/abstract/64\">",
"     64",
"    </a>",
"    ]. From these clinical activities, information will emerge concerning the immune response to xenotransplantation and the risks of infection.",
"   </p>",
"   <p>",
"    It can be anticipated that a next step will be \"bridge\" transplants, in which a porcine kidney, heart, or liver are implanted to provide temporary support until more definitive treatment can be performed. It is difficult to envision how and under which conditions a porcine kidney might be used as a clinical bridge.",
"   </p>",
"   <p>",
"    Bridge transplants will provide important information about the manifestation and control of the vascular responses to xenotransplantation. Only when these responses are effectively controlled over a period of months is it likely that the porcine kidney will be used as a permanent xenogeneic transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The transplantation of cells, tissues, and organs between individuals of different species is referred to as xenotransplantation. The shortage of human kidneys for transplantation is currently severe, resulting in a heightened risk of morbidity and mortality, and longer period of waiting for many in need of transplants. Xenotransplantation would eliminate this fundamental problem of clinical transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possible sources of xenografts are non-human primates and non-primates, particularly the pig. Specific benefits with using swine xenografts include availability in unlimited numbers, organs of appropriate size, and a limited risk of transmitting infectious agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sources of xenografts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are significant hurdles to the successful application of xenotransplantation. These hurdles include the immunological responses of the recipient against the graft, physiological limitations of the graft, infection, and ethical considerations. Powerful immunologic reactions lead to hyperacute, acute vascular, cellular, and chronic rejection. Specific measures unique to xenotransplantation have been utilized in the attempt to overcome these issues. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Barriers to xenotransplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If biologic hurdles are overcome, kidney xenotransplantation could be used for select populations. These may include presensitized individuals, young infants with kidney failure, and others. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Possible future indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Future approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/1\">",
"      Jaboulay, M. De reins au pli du coude par soutures arterielles et veineuses. Lyon Med 1906; 107:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/2\">",
"      Cascalho M, Platt JL. Xenotransplantation and other means of organ replacement. Nat Rev Immunol 2001; 1:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/3\">",
"      White, DJ. Genetic engineering of pigs to provide organs for xenotransplantation. Curr Opin Organ Transplant 2006; 11:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/4\">",
"      Platt JL. New directions for organ transplantation. Nature 1998; 392:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/5\">",
"      Pierson RN 3rd. Current status of xenotransplantation. JAMA 2009; 301:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/6\">",
"      REEMTSMA K, MCCRACKEN BH, SCHLEGEL JU, et al. RENAL HETEROTRANSPLANTATION IN MAN. Ann Surg 1964; 160:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/7\">",
"      Starzl TE, Fung J, Tzakis A, et al. Baboon-to-human liver transplantation. Lancet 1993; 341:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/8\">",
"      Ekser B, Rigotti P, Gridelli B, Cooper DK. Xenotransplantation of solid organs in the pig-to-primate model. Transpl Immunol 2009; 21:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/9\">",
"      Hammerman MR. Xenotransplantation of developing kidneys. Am J Physiol Renal Physiol 2002; 283:F601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/10\">",
"      Rogers SA, Talcott M, Hammerman MR. Transplantation of pig metanephroi. ASAIO J 2003; 49:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/11\">",
"      Cascalho M, Platt JL. New technologies for organ replacement and augmentation. Mayo Clin Proc 2005; 80:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/12\">",
"      Yokoo T, Fukui A, Matsumoto K, Okabe M. Stem cells and kidney organogenesis. Front Biosci 2008; 13:2814.",
"     </a>",
"    </li>",
"    <li>",
"     Cascalho M, Platt JL. Emerging strategies in kidney transplantation. In: Chronic Kidney Disease, Dialysys, and Transplantation, 3, Himmelfarb J, Sayegh MH.  (Eds), Elsevier, Philadelphia 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/14\">",
"      Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153:3791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/15\">",
"      Brauer RB, Baldwin WM 3rd, Daha MR, et al. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151:7240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/16\">",
"      Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995; 181:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/17\">",
"      Crikis S, Cowan PJ, d'Apice AJ. Intravascular thrombosis in discordant xenotransplantation. Transplantation 2006; 82:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/18\">",
"      Schmelzle M, Schulte Esch J 2nd, Robson SC. Coagulation, platelet activation and thrombosis in xenotransplantation. Curr Opin Organ Transplant 2010; 15:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/19\">",
"      Sablinski, T, Latinne, D, Gianello, P, et al. Xenotransplantation of pig kidneys to nonhuman primates: I. development of the model. Xenotransplantation 1995; 2:264.",
"     </a>",
"    </li>",
"    <li>",
"     Platt, JL. Complement Inhibitors. In: Inflammation: Basic Principles and Clinical Correlates, Lippincott-Raven, Philadelphia, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/21\">",
"      Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/22\">",
"      Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/23\">",
"      Shimizu A, Yamada K, Yamamoto S, et al. Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005; 16:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/24\">",
"      Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/25\">",
"      McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1:423.",
"     </a>",
"    </li>",
"    <li>",
"     Cozzi, E, Yannoutsos, N, Langford, GA, et al. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Xenotransplantation: The transplantation of organs and tissues between species, Springer, Berlin, 1997. p.665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/27\">",
"      Zhou CY, McInnes E, Copeman L, et al. Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor. Xenotransplantation 2005; 12:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/28\">",
"      Dai Y, Vaught TD, Boone J, et al. Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002; 20:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/29\">",
"      Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/30\">",
"      Cooper DK. Clinical xenotransplantion--how close are we? Lancet 2003; 362:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/31\">",
"      Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/32\">",
"      Zhong R. Gal knockout and beyond. Am J Transplant 2007; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/33\">",
"      Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/34\">",
"      Lin Y, Vandeputte M, Waer M. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts. J Immunol 1998; 160:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/35\">",
"      Platt JL, Lin SS, McGregor CG. Acute vascular rejection. Xenotransplantation 1998; 5:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/36\">",
"      Bannett AD, McAlack RF, Morris M, et al. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplantation. Transplant Proc 1989; 21:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/37\">",
"      Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol 2004; 172:5143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/38\">",
"      Dorling A. Transplant Accommodation - Are the lessons learned from xenotransplantation pertinent for clinical allotransplantation. Am J Transplant 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/39\">",
"      Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: expression of \"protective genes\" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/40\">",
"      Vogt BA, Shanley TP, Croatt A, et al. Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme oxygenase-dependent resistance to renal injury. J Clin Invest 1996; 98:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/41\">",
"      Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/42\">",
"      Ildstad ST, Vacchio MS, Markus PM, et al. Cross-species transplantation tolerance: rat bone marrow-derived cells can contribute to the ligand for negative selection of mouse T cell receptor V beta in chimeras tolerant to xenogeneic antigens (mouse + rat----mouse). J Exp Med 1992; 175:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/43\">",
"      Li H, Ricordi C, Demetris AJ, et al. Mixed xenogeneic chimerism (mouse+rat--&gt;mouse) to induce donor-specific tolerance to sequential or simultaneous islet xenografts. Transplantation 1994; 57:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/44\">",
"      Sachs, DH, Sablinski, T. Tolerance across discordant xenogeneic barriers. Xenotransplantation 1995; 2:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/45\">",
"      Sandrin MS, McKenzie IF. Recent advances in xenotransplantation. Curr Opin Immunol 1999; 11:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/46\">",
"      Chen D, Weber M, McVey JH, et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/47\">",
"      Sprangers, B, Waer, M, Billiau, AD. Xenograft rejection and the innate immune system. Curr Opin Organ Transplant 2007; 12:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/48\">",
"      Zaidi A, Schmoeckel M, Bhatti F, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998; 65:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/49\">",
"      McCurry KR, Parker W, Cotterell AH, et al. Humoral responses to pig-to-baboon cardiac transplantation: implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum Immunol 1997; 58:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/50\">",
"      Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/51\">",
"      Zaidi A, Bhatti F, Schmoeckel M, et al. Kidneys from HDAF transgenic pigs are physiologically compatible with primates. Transplant Proc 1998; 30:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/52\">",
"      Soin B, Smith KG, Zaidi A, et al. Physiological aspects of pig-to-primate renal xenotransplantation. Kidney Int 2001; 60:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/53\">",
"      Patience, C, Stoye, J. Infectious risk of clinical xenotransplantation. Curr Opin Organ Transplant 2004; 9:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/54\">",
"      Fishman JA, Patience C. Xenotransplantation: infectious risk revisited. Am J Transplant 2004; 4:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/55\">",
"      Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/56\">",
"      Paradis K, Langford G, Long Z, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999; 285:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/57\">",
"      Ogle BM, Butters KA, Plummer TB, et al. Spontaneous fusion of cells between species yields transdifferentiation and retroviral transfer in vivo. FASEB J 2004; 18:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/58\">",
"      Platt JL. Xenotransplantation. New risks, new gains. Nature 2000; 407:27, 29.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Xenotransplantation. National Academy Press, Washington, 1996.",
"    </li>",
"    <li>",
"     Animal-to-human transplants: the ethics of xenotransplantation. London: The Nuffield Council on Bioethics, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/61\">",
"      Sykes M, d'Apice A, Sandrin M, IXA Ethics Committee. Position paper of the Ethics Committee of the International Xenotransplantation Association. Transplantation 2004; 78:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/62\">",
"      Cooper DK, Tseng YL, Saidman SL. Alloantibody and xenoantibody cross-reactivity in transplantation. Transplantation 2004; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/63\">",
"      Wong BS, Yamada K, Okumi M, et al. Allosensitization does not increase the risk of xenoreactivity to alpha1,3-galactosyltransferase gene-knockout miniature swine in patients on transplantation waiting lists. Transplantation 2006; 82:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13912/abstract/64\">",
"      Rood PP, Cooper DK. Islet xenotransplantation: are we really ready for clinical trials? Am J Transplant 2006; 6:1269.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7323 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13912=[""].join("\n");
var outline_f13_37_13912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF XENOGRAFTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BARRIERS TO XENOTRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunologic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hyperacute rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute vascular rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cellular rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chronic rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physiologic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ethical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSSIBLE FUTURE INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Presensitized patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FUTURE APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7323|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?15/59/16317\" title=\"algorithm 1\">",
"      Biologic rx to xenotransplant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=related_link\">",
"      General principles of kidney transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13913="Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)";
var content_f13_37_13913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13913/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13913/contributors\">",
"     Brian S Harvey, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13913/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13913/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/37/13913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2509429\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondritis dissecans (OCD) refers to osteonecrosis of subchondral bone and was first described by Ambroise Pare in 1558 after finding loose bodies in a patient&rsquo;s knee. Paget named the process &ldquo;quiet necrosis&rdquo; when describing two patients with knee pain in 1870 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 1887 to 1888, Konig was given credit for the original description based on his theory that the loose bodies resulted from a combination of trauma acting on the necrotic lesion underneath.",
"   </p>",
"   <p>",
"    Konig&rsquo;s original description was thought to be of inflammatory dissection; however, throughout the years, inflammation was never revealed, making the name osteochondritis a misnomer. Over the next 75 years, multiple physicians noted similar lesions throughout the body. Despite having no evidence of inflammation on histologic examination, the name osteochondritis has prevailed.",
"   </p>",
"   <p>",
"    OCD most often occurs in the knee, elbow, or ankle of the school-age or adolescent child where it causes pain. Plain radiographs are frequently diagnostic although magnetic resonance imaging is typically necessary to further characterize the lesion. Initial treatment consists of rest, nonsteroidal anti-inflammatory medicines, avoidance of high intensity activities, and physical therapy. Patients who are skeletally immature frequently do well with nonoperative therapy. Patients with large lesions or in whom intraarticular foreign bodies develop usually need surgery.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical manifestations and diagnosis of OCD. The management of OCD and other causes of knee, elbow, or ankle pain in the young athlete are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=see_link\">",
"       \"Management of osteochondritis dissecans (OCD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"       \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=see_link\">",
"       \"Elbow injuries in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"       \"Clinical features and management of ankle pain in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753872\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondritis dissecans (OCD) is defined as osteonecrosis of subchondral bone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/3\">",
"     3",
"    </a>",
"    ]. Specifically, OCD is a localized lesion in which a segment of subchondral bone and articular cartilage separates from the underlying bone, leaving either a stable or unstable fragment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several classification systems for OCD lesions that are based upon plain radiograph, magnetic resonance imaging, or arthroscopic findings as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. On plain radiograph, the severity of the OCD lesion is defined according to Berndt and Harty as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I - Small compressed, nondisplaced fragment",
"     </li>",
"     <li>",
"      Stage II - Partially detached fragment",
"     </li>",
"     <li>",
"      Stage III - Completely detached, nondisplaced foreign body",
"     </li>",
"     <li>",
"      Stage IV - Completely detached and displaced foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Juvenile OCD refers to the presence of the lesion in patients with open physes (growth plates (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/7\">",
"     7",
"    </a>",
"    ]. Adult OCD describes the condition in skeletally mature patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753890\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of OCD is unknown. Proposed etiologies include repetitive micro-trauma, local ischemia after a single injury, and genetic predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Juvenile OCD is associated with high activity level in school-age children and adolescents which favors repetitive trauma as a primary mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/7\">",
"     7",
"    </a>",
"    ]. With initial trauma a focal area of hypovascularity, necrosis, and collapse of the bone develops that can lead to chondromalacia, fracture, and absorption of necrotic bone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/10\">",
"     10",
"    </a>",
"    ]. The necrotic bone is then replaced by subchondral trabeculae or cartilage. The healing of subchondral bone requires revascularization via the ingrowth of capillaries across the fracture line. If revascularization does not occur, OCD may develop [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/11\">",
"     11",
"    </a>",
"    ]. The overlying articular surface usually remains viable because it receives its blood supply from the synovium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/12\">",
"     12",
"    </a>",
"    ]. As the lesion progresses, focal areas of demineralization and repeated shear forces cause detachment of the bone and overlying cartilage. Repeated axial loading with increased valgus or varus stress may play an important role in this phase, particularly in the knee. OCD may also develop after an isolated injury (eg, ankle inversion or direct blow to the knee or elbow).",
"   </p>",
"   <p>",
"    OCD lesions of the elbow are thought to be, at least in part, due to chronic valgus stress to the elbow which compromises the tenuous blood supply to the capitellum and micro-trauma from chronic compression during overhead activities (eg, throwing, gymnastics) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/9\">",
"     9",
"    </a>",
"    ]. These repeated injuries cause degeneration of subchondral bone.",
"   </p>",
"   <p>",
"    OCD lesions can also occur in a familial pattern and have been described in identical twins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Thus, genetic predisposition appears to play a role in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753897\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCD lesions are a rare cause of joint pain in children. The prevalence of OCD lesions, particularly in the knee, is estimated to be 15 to 29 per 100,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/15\">",
"     15",
"    </a>",
"    ]. Boys are affected about two to three times as often as girls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/8\">",
"     8",
"    </a>",
"    ]. Repeated trauma or overuse is frequently reported. Sport specific risk factors by anatomic region include sports associated with high frequencies of knee or ankle injuries (eg, soccer, American football, basketball) and, for the elbow, the overhead throwing athlete (eg, baseball pitcher) or gymnast [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical locations of an OCD lesion with relative frequencies are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,9,17-21\">",
"     1,9,17-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knee &ndash; 75 percent of patients, often occurring in lateral portion of the medial femoral condyle",
"     </li>",
"     <li>",
"      Elbow &ndash; 6 percent of patients, usually found in the capitellum",
"     </li>",
"     <li>",
"      Ankle &ndash; 4 percent of patients, particularly the talar dome (57 percent medial and 43 percent lateral)",
"     </li>",
"     <li>",
"      Other joints &ndash; Approximately 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OCD typically occurs in patients between the ages of 10 and 20 years although adults can also be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1\">",
"     1",
"    </a>",
"    ]. Specific age of presentation also depends upon the location of the OCD lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,9,17-21\">",
"     1,9,17-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of OCD lesions of the knee peaks in the preteen years, but can occur at any age.",
"     </li>",
"     <li>",
"      Osteochondritis dissecans lesions of the elbow are typically found in athletes in the teen years after the physis has closed.",
"     </li>",
"     <li>",
"      The ankle OCD lesion is rare in the pediatric population, mainly occurring in adults with the average age being 21 years of age. There is an association with trauma to the ankle, particularly in lateral talar dome lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2510199\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCD typically presents with pain in the knee, elbow, or ankle that may begin with a specific injury or can develop over several months in highly active patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. The pain is worsened by exercise. Crepitus, catching, or locking of the joint may occur during the later stages of OCD, especially if a loose foreign body is present in the joint. The diagnosis can frequently be made by clinical findings and judicious use of imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753904\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentations of OCD lesions are dependent on the location, size and severity of the lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Knee",
"      </strong>",
"      &ndash; Early or small OCD lesions found in the knee typically will present with nonspecific, poorly localized knee pain with activity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/22\">",
"       22",
"      </a>",
"      ]. As the process progresses, gradual onset, stiffness, and intermittent swelling during or after activity occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,7\">",
"       1,7",
"      </a>",
"      ]. When advanced or larger lesions are present, the patient may experience catching or locking, especially if a loose foreign body is present [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1\">",
"       1",
"      </a>",
"      ]. Loss of range of motion, however, is uncommon.",
"     </li>",
"     <li>",
"      <strong>",
"       Elbow",
"      </strong>",
"      &ndash; OCD lesions of the elbow, particularly the capitellum, present with onset of lateral elbow pain that gradually worsens with activity. The pain is often described as dull, is poorly localized to the lateral elbow, and in contrast to patients with OCD of the knee, may be associated with decreased range of motion. Mechanical symptoms of popping, locking, and catching suggest advanced disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Ankle",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      With",
"      <strong>",
"      </strong>",
"      OCD lesions of the talar dome, patients typically present with a history of an ankle inversion injury that does not improve with typical conservative treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/23\">",
"       23",
"      </a>",
"      ]. Posteromedial lesions occur when the foot is plantarflexed during inversion, whereas anterolateral lesions occur when the foot is dorsiflexed. Symptoms include pain, persistent swelling, stiffness, weakness, mechanical sensation (eg, popping, clicking, or locking), and with advanced lesions, a loose body sensation (eg, something floating around) in the ankle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753911\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint-specific physical examination findings of OCD are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Knee",
"      </strong>",
"      &ndash; On inspection, swelling may or may not be present. Full range of motion is typically found. The clinician should palpate both femoral condyles for tenderness with the knee in flexion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/24\">",
"       24",
"      </a>",
"      ]. OCD is suggested by tenderness to palpation with the knee flexed and pressure directed over the medial femoral condyle, just medial to the inferior pole of the patella [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/3\">",
"       3",
"      </a>",
"      ]. Crepitus may also be noted. Patients with chronic symptoms may display an antalgic gait or alteration of gait with the foot of the affected side rotated laterally to reduce the pain of weightbearing [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,3\">",
"       1,3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The Wilson sign is a provocative test that can identify OCD lesions present at the lateral aspect of the medial femoral condyle and is performed as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]: The patient is asked to sit with the knee flexed over the examining table. The knee is then extended actively with the tibia rotated medially. With increasing extension, at approximately 30 degrees of flexion, the pain in the knee should increase. At this point, the patient is asked to stop, rotate the tibia laterally, and the pain disappears. Although helpful in establishing the diagnosis of OCD when present, the Wilson sign is negative in approximately 75 percent of patients with juvenile OCD found on imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/9,27,28\">",
"       9,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Elbow",
"      </strong>",
"      &ndash; Patients with OCD of the elbow often have mild swelling over the capitellum, restricted joint mobility (ie, decreased extension and reduced supination and pronation), and tenderness to palpation at the anterolateral aspect of the elbow [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,9\">",
"       1,9",
"      </a>",
"      ]. The radiocapitellar compression test is performed by asking the patient to pronate and supinate the affected forearm with the elbow in full extension [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,9,17\">",
"       1,9,17",
"      </a>",
"      ]. The test is considered positive if supination or pronation causes pain. Locking of the elbow suggests formation of a loose foreign body.",
"     </li>",
"     <li>",
"      <strong>",
"       Ankle",
"      </strong>",
"      &ndash; Physical examination of the patient with OCD lesions of the talar dome shows tenderness when the ankle is palpated while plantar flexing and dorsiflexing the ankle to bring the anterior aspect of the articular surface of the talus into the fingertips of the examiner [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,18\">",
"       1,18",
"      </a>",
"      ]. Other findings include swelling and joint effusion in patients with unstable or loose foreign bodies. Range of motion may also be reduced although it is preserved in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753918\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753926\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected OCD should initially undergo plain radiographs of the affected joint. However, radiographs can be normal, especially in patients with small, compressed fragments (Stage I OCD) (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H21753872\">",
"     'Definition'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=see_link&amp;anchor=H314565#H314565\">",
"     \"Management of osteochondritis dissecans (OCD)\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suggested views and typical findings by joint are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knee &ndash; AP, lateral, tunnel, and Merchant (or sunrise) views [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"      <br/>",
"      Most OCD lesions are found on the medial femoral condyle and consist of a subchondral bony fragment surrounded by a crescent-shaped radiolucency (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69442 \" href=\"UTD.htm?25/56/26510\">",
"       image 1",
"      </a>",
"      ). Tunnel views of the knee often provide the best visualization of the lesions in this location (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85768 \" href=\"UTD.htm?3/18/3362\">",
"       image 2",
"      </a>",
"      ). Less commonly, lesions may be present on the lateral femoral condyle, femoral trochlea, or patella. Patellar lesions may only be visible on the Merchant (sunrise) view.",
"     </li>",
"     <li>",
"      Elbow &ndash; AP in full extension, AP in 45 degrees of flexion and a lateral view in 90 degrees of flexion.",
"      <br/>",
"      <br/>",
"      Radiographs may demonstrate lateral anterior capitellum flattening or, in more advanced disease, a crater and subchondral sclerosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85769 \" href=\"UTD.htm?2/41/2704\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ankle &ndash; Oblique, mortise, and plantar flexed views [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,30\">",
"       1,30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Initial radiographs are normal in approximately one-third of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/31\">",
"       31",
"      </a>",
"      ]. Medial dome OCD of the talus is seen best on the anteroposterior (AP) view of the ankle in maximal plantarflexion and appears as a deep, cup-shaped lesion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85770 \" href=\"UTD.htm?42/18/43298\">",
"       image 4",
"      </a>",
"      ). Lateral lesions are best seen on the mortise view with the ankle in dorsiflexion. These lesions are shallow and wafer-like.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon small case series, we suggest radiographic views of both knees and ankles regardless of symptoms because bilateral disease is found in up to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/21,32\">",
"     21,32",
"    </a>",
"    ]. Furthermore, comparison views with the contralateral knee help differentiate OCD from normal variations in ossification of the femoral condyles in skeletally immature patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon our experience and case reports, we do not routinely obtained contralateral radiographs when assessing patients for osteochondritis dissecans of the elbow unless patients report bilateral pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17944402\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the use of MRI in the evaluation and management of OCD is limited to small observational studies and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/8,20,28,36-39\">",
"     8,20,28,36-39",
"    </a>",
"    ]. MRI has the capability of assessing the surrounding cartilage and subchondral bone that is not seen on conventional radiographs, avoids ionizing radiation, and has superior detail and definition of the surround soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, MRI is the imaging study of choice for diagnosis of OCD in patients with normal plain radiographs but persistent symptoms and for grading of lesions in patients with OCD demonstrated on plain radiographs. In most instances, MRI without contrast provides adequate diagnostic and staging information. In patients for whom stability of the lesion is uncertain, gadolinium contrast can help determine if blood supply to the bony fragment is adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. In younger children, MRI also helps to differentiate normal ossification centers of the distal femur from OCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In skeletally mature patients (adult OCD), MRI of the knee is typically performed to further characterize lesions found on plain radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/39\">",
"     39",
"    </a>",
"    ]. This approach permits grading (",
"    <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"     table 1",
"    </a>",
"    ) and provides information regarding the stability of the bony fragment. Limited evidence suggests that MRI has high diagnostic sensitivity and specificity (100 percent for both in small observational studies) for OCD and is also concordant with arthroscopic findings with respect to bone fragment stability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, MRI appears useful for confirming the diagnosis and determining the need for surgery in patients with adult OCD.",
"   </p>",
"   <p>",
"    In contrast, MRI findings in skeletally immature patients (juvenile OCD) require careful clinical correlation and should",
"    <strong>",
"     not",
"    </strong>",
"    be solely relied upon to determine the need for operative treatment. In these patients, MRI also has a high diagnostic sensitivity (approximately 100 percent), but diagnostic specificity is low (approximately 10 to 15 percent) and predicted stability of the bony fragment lacks concordance with arthroscopic findings in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/37\">",
"     37",
"    </a>",
"    ]. Specifically, Stage III lesions on MRI (large signal behind the bony fragment), frequently have normal surface cartilage with no fragment instability on arthroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI has similar utility for establishing the diagnosis of OCD in the elbow and ankle. MRI can be especially helpful in symptomatic patients in whom plain radiographs are normal. MRI also provides a means to identify unstable lesions in these joints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/20,36\">",
"     20,36",
"    </a>",
"    ]. In patients with capitellar OCD, MRI is particularly helpful for identifying cartilaginous foreign bodies that are usually missed by plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/20\">",
"     20",
"    </a>",
"    ]. In patients with OCD lesions of the dome of the talus, MRI has been useful for both preoperative evaluation and follow-up examination.",
"   </p>",
"   <p>",
"    MRI is less useful for determining healing of OCD lesions because clinical healing may not correlate with imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/7,18\">",
"     7,18",
"    </a>",
"    ], and in patients with operative repair, bony edema from instrumentation interferes with identification of healing during the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17944530\">",
"    <span class=\"h3\">",
"     Other imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT), single photon emission computed tomography (SPECT), ultrasound (US), and radionuclide bone scan have all been used in the evaluation and management of OCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/36,41-46\">",
"     36,41-46",
"    </a>",
"    ]. However, in most patients, plain radiographs and, if indicated, magnetic resonance imaging are sufficient to establish the diagnosis of OCD and, along with clinical findings, determine further management.",
"   </p>",
"   <p>",
"    In some patients with loose intraarticular bony foreign bodies, especially involving the talus, CT may aide in characterizing the location and appearance of the bony fragment for surgical planning and management [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/36,44\">",
"     36,44",
"    </a>",
"    ]. After surgery, conventional CT and SPECT can theoretically provide information about the metabolic state in bone healing and how well the bone fragment is being integrated during the time period when bony edema from the repair interferes with MRI results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/41,45\">",
"     41,45",
"    </a>",
"    ]. However, the use of CT and SPECT for this indication is not routine and requires further study.",
"   </p>",
"   <p>",
"    Ultrasound in the hands of experienced operators can identify OCD lesions of the knee and elbow and provide information on stability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/43,47\">",
"     43,47",
"    </a>",
"    ]. As an example, in a small case series of 27 patients between 11 and 20 years of age with capitellar OCD, US identified unstable lesions that were confirmed in 14 of 15 patients at arthroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/43\">",
"     43",
"    </a>",
"    ]. However, US is not routinely used or available for this purpose and provides information that is inferior to MRI.",
"   </p>",
"   <p>",
"    Radionuclide bone scans have largely been replaced by MRI for the diagnosis of OCD in symptomatic patients with normal plain radiographs because of radiation exposure and limited information provided by the images. When compared to MRI, bone scans do not give detailed information about the anatomy of the bone or the articular cartilage which would be necessary for classification and therapeutic planning [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/46\">",
"     46",
"    </a>",
"    ]. Furthermore, the radionuclide tracer from a bone scan remains in the lesion for long amounts of time, even after the lesion has healed, thus limiting the ability to determine resolution of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2510300\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggestive clinical findings of OCD include gradually worsening joint pain over several months in active patients or, for OCD of the talus, lingering pain after an ankle inversion injury. Bony tenderness over the typical locations (medial femoral condyle, anterolateral elbow, or medial or lateral talar dome), or, with advanced disease, popping, catching, or locking of the joint may be elicited. The diagnosis of OCD can frequently be made based upon plain radiographic findings of the characteristic bony fragment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85768 \" href=\"UTD.htm?3/18/3362\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85769 \" href=\"UTD.htm?2/41/2704\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85770 \" href=\"UTD.htm?42/18/43298\">",
"     image 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2510199\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with typical clinical and radiographic findings of OCD, magnetic resonance imaging is not needed to establish the diagnosis but may be helpful in determining further management. Magnetic resonance imaging may be necessary for diagnosis of OCD in patients with normal plain radiographs but persistent characteristic symptoms or to differentiate OCD from other joint derangements. (See",
"    <a class=\"local\" href=\"#H17944402\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21753968\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753968\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions have clinical features that overlap with OCD. Most can be identified by a careful history and physical examination and plain radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753976\">",
"    <span class=\"h2\">",
"     Knee",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753984\">",
"    <span class=\"h3\">",
"     Torn meniscus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meniscus tears are typically acute in nature and have a known or suspected mechanism of injury. However, in older patients the suspected mechanism may be a minor movement resulting in pain and swelling, versus an adolescent patient in which the traumatic event is likely to be more obvious. Meniscal tears typically occur when the knee twists with the foot fixed during activities, such as football (soccer), American football, and basketball. Pain and swelling vary depending upon the size of the tear and joint effusion is common. Patients with meniscal tears often have joint line tenderness, inability to fully extend the knee, inability to squat or kneel, and have discomfort with provocative tests such as the Thessaly test (standing on one leg with the knee flexed to 20 degrees followed by internal and external rotation of the knee) or McMurray maneuver (",
"    <a class=\"graphic graphic_picture graphicRef52712 \" href=\"UTD.htm?1/59/1969\">",
"     picture 1",
"    </a>",
"    ). Patients with OCD may have some of these findings depending on the site of the OCD lesion. Confirmation of clinical findings, when necessary, is accomplished with magnetic resonance imaging or arthroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H3#H3\">",
"     \"Meniscal injury of the knee\", section on 'Mechanism and presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H5#H5\">",
"     \"Meniscal injury of the knee\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link&amp;anchor=H389395771#H389395771\">",
"     \"Meniscal injury of the knee\", section on 'Diagnosis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753991\">",
"    <span class=\"h3\">",
"     Symptomatic discoid meniscus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some individuals are born with a variant meniscus in the shape of a disk. Although most commonly asymptomatic, a discoid meniscus can cause clicking, popping or catching with pain over the lateral joint line (the &ldquo;snapping knee syndrome&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/48\">",
"     48",
"    </a>",
"    ]. A tear in a discoid meniscus may also be accompanied by effusion and clinical findings of meniscal tears including decreased knee extension, inability to squat or kneel, and discomfort with provocative tests. Magnetic resonance imaging or diagnostic arthroscopy can confirm the diagnosis. In contrast, OCD typically causes medial knee pain and does not affect knee range of motion.",
"   </p>",
"   <p>",
"    Asymptomatic discoid menisci require no operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/48\">",
"     48",
"    </a>",
"    ]. Symptomatic discoid menisci initially respond well to surgery although information on long-term outcomes is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21753998\">",
"    <span class=\"h3\">",
"     Medial plica syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medial plica syndrome involves irritation of the synovial remnant in the knee, which can become inflamed with repetitive trauma. Patients complain of catching or popping along with nondescript knee pain on the medial joint. Tenderness is typically found over the medial aspect of the knee. Careful palpation with the knee at 90 degrees of flexion may reveal a firm, tender ridge of tissue running either parallel or slightly obliquely to the medial border of the patellar which helps to differentiate OCD from plica syndrome. Examination may also reveal tight quadriceps and hamstring muscles and positive medial patellar plica (",
"    <a class=\"graphic graphic_figure graphicRef83265 \" href=\"UTD.htm?18/51/19248\">",
"     figure 2",
"    </a>",
"    ) and knee extension (",
"    <a class=\"graphic graphic_figure graphicRef83266 \" href=\"UTD.htm?2/12/2241\">",
"     figure 3",
"    </a>",
"    ) tests which are negative in patients with OCD. Arthroscopy provides a definitive diagnosis if a thickened, fibrotic plica is demonstrated, but is only performed when other diagnoses are considered or when conservative treatment fails. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1752?source=see_link&amp;anchor=H10354545#H10354545\">",
"     \"Plica syndrome\", section on 'Diagnosis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754005\">",
"    <span class=\"h3\">",
"     Patellofemoral pain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome is a clinical diagnosis that is suggested by a dull, diffuse anterior knee pain that is worsened by activity, squatting, using stairs, or prolonged sitting and often occurs in runners. Unlike OCD, the physical examination shows varying degrees of patellar misalignment, pain with squatting, and pain with resisted quadriceps contraction. In addition, special tests for patellofemoral pain syndrome (eg, patellofemoral compression test, patellar glide, or apprehension test) are frequently positive. The performance of these tests are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link&amp;anchor=H15#H15\">",
"     \"Patellofemoral pain syndrome\", section on 'Special tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754012\">",
"    <span class=\"h2\">",
"     Elbow",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754020\">",
"    <span class=\"h3\">",
"     Panner disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panner disease is an osteochondrosis characterized by atypical ossification, necrosis, and regeneration of the distal humeral capitellum epiphysis and secondary ossification centers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. It occurs most frequently in boys between 7 and 10 years of age and is almost always unilateral and in the dominant (ie, throwing) arm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13913/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. The pain increases with continued throwing and decreases with rest. Radiographs typically show fragmentation (areas of sclerosis and rarefaction) of the capitellum with an irregular joint surface similar to OCD. In contrast to OCD of the elbow, Panner disease occurs in school-age children as opposed to adolescents, does not produce a loose foreign body, and spontaneously resolves with rest.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754027\">",
"    <span class=\"h3\">",
"     Little league elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little league elbow specifically relates to apophysitis of the medial epicondyle due to repeated valgus stress. This condition frequently occurs in throwing athletes, particularly pitchers. When compared to OCD, physical examination typically demonstrates medial epicondyle pain rather than anterolateral pain and the radiocapitellar compression test is negative. Radiographs are typically normal. (See",
"    <a class=\"local\" href=\"#H21753911\">",
"     'Physical examination'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=see_link&amp;anchor=H25#H25\">",
"     \"Elbow injuries in the young athlete\", section on 'Little league elbow'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754034\">",
"    <span class=\"h3\">",
"     Medial epicondyle fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avulsion fractures typically occur after a fall on an outstretched hand. Patients may experience a pop with acute swelling. Radiographs should be obtained, showing the avulsion fracture which differentiates this injury from OCD (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79471 \" href=\"UTD.htm?6/41/6800\">",
"     image 5",
"    </a>",
"    ). The treatment of these fractures is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=see_link&amp;anchor=H17#H17\">",
"     \"Epicondylar and transphyseal elbow fractures in children\", section on 'Medial epicondylar fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754041\">",
"    <span class=\"h3\">",
"     Epicondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral (tennis elbow) or medial epicondylitis (golfer&rsquo;s elbow) can present in the pediatric population, but are more commonly seen in adolescents and adults. Lateral epicondylitis presents with pain at the lateral epicondyle where the extensor carpi radialis brevis inserts. Medial epicondylitis presents with pain medially where the flexor and pronator muscles insert. Unlike OCD, epicondylitis is not associated with locking and the capitellum is unaffected. Plain radiographs are typically normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link&amp;anchor=H7#H7\">",
"     \"Epicondylitis (tennis and golf elbow)\", section on 'Clinical presentation and examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754048\">",
"    <span class=\"h2\">",
"     Talus",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754056\">",
"    <span class=\"h3\">",
"     Ankle sprain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to OCD, ankle sprains often arise from inversion injuries and cause lateral or medial ankle pain. The anterior talofibular ligament is most commonly involved. Physical examination demonstrates pain and swelling over the ligamentous complex. Depending upon the degree of sprain, ligamentous laxity may be noted on anterior drawer and talar tilt tests. Ankle sprains differ from OCD by their resolution over several weeks and by the absence of bony findings on plain radiographs. The clinical features and treatment of ankle sprains are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754063\">",
"    <span class=\"h3\">",
"     Os trigonum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The os trigonum is the persistence of the lateral ossification center on the posterior aspect of the talus after skeletal maturation. The groove for the flexor hallucis longus on the posterior aspect of the talus has an elongated lateral wall called Stieda's process. The os trigonum can cause pain during activities requiring repetitive plantar flexion (eg, swimming, gymnastics, dancing); although, patients with this condition are frequently asymptomatic.",
"   </p>",
"   <p>",
"    Patients with os trigonum syndrome describe pain in the posterior lateral aspect of the ankle; symptoms may be exacerbated when walking downhill. Tenderness is present at the posterolateral aspect of the ankle. Pain is accentuated by squatting, resisted plantarflexion, or dorsiflexion of the great toe because these maneuvers cause the flexor hallucis longus (FHL) to push against the ossicle as the FHL passes over the talus. Plantarflexion of the foot with axial loading to the heel reproduces the symptoms. Plain radiographs (lateral ankle and lateral ankle in plantar flexion) demonstrate the presence of the os or Stieda's process. Os trigonum differs from OCD by the location of pain (posterior instead of medial or lateral) and by radiographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link&amp;anchor=H53#H53\">",
"     \"Clinical features and management of ankle pain in the young athlete\", section on 'Os trigonum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754070\">",
"    <span class=\"h3\">",
"     Tarsal coalition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tarsal coalition, a fibrous bony connection between two or more of the tarsal bones, is a condition that is present at birth but becomes symptomatic only during the second decade as the coalition(s) ossify. Calcaneonavicular and talocalcaneal coalitions are most common and typically occur bilaterally (",
"    <a class=\"graphic graphic_picture graphicRef52540 \" href=\"UTD.htm?35/33/36375\">",
"     picture 2",
"    </a>",
"    ). Ossification limits motion at the tarsal joint. Patients may complain of pain over the subtalar joint of the foot. The pain worsens with activity, walking on uneven ground, or running. Physical examination findings include a rigid flatfoot, hindfoot valgus, loss of subtalar motion, and limited, painful inversion of the foot. However, these findings are not specific and may overlap with clinical findings of OCD. Tarsal coalition can be differentiated from OCD by oblique radiographs or computed tomography (CT) scan of the subtalar joint which demonstrate the bony coalition (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66078 \" href=\"UTD.htm?38/3/38975\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H315016\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of OCD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=see_link\">",
"     \"Management of osteochondritis dissecans (OCD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21754098\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteochondritis dissecans (OCD) is a localized lesion in which a segment of subchondral bone and articular cartilage separates from the underlying bone, leaving either a stable or unstable bone fragment. (See",
"      <a class=\"local\" href=\"#H21753872\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=see_link&amp;anchor=H314565#H314565\">",
"       \"Management of osteochondritis dissecans (OCD)\", section on 'Definition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      OCD lesions are a rare cause of joint pain in children and are associated with repeated trauma or overuse in athletes. Boys are affected about two to three times as often as girls. The knee is most commonly affected followed by the elbow and ankle. (See",
"      <a class=\"local\" href=\"#H21753897\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OCD typically presents with pain in the knee, elbow, or ankle that may begin with a specific injury or can develop over several months in highly active patients. The pain is worsened by exercise. Crepitus, catching, or locking of the joint may occur during the later stages of OCD, especially if a loose foreign body is present in the joint. History and physical examination findings vary by the involved joint. (See",
"      <a class=\"local\" href=\"#H2510199\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected OCD should initially undergo plain radiographs of the affected joint. OCD lesions consist of a subchondral bony fragment surrounded by a crescent-shaped radiolucency and vary in location depending upon the involved joint (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69442 \" href=\"UTD.htm?25/56/26510\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85770 \" href=\"UTD.htm?42/18/43298\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85769 \" href=\"UTD.htm?2/41/2704\">",
"       image 3",
"      </a>",
"      ). However, radiographs can be normal, especially in patients with small, compressed fragments. (See",
"      <a class=\"local\" href=\"#H21753926\">",
"       'Plain radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging is suggested for the diagnosis of OCD in patients with normal plain radiographs but persistent symptoms and for grading of lesions in patients with OCD demonstrated on plain radiographs (",
"      <a class=\"graphic graphic_table graphicRef85755 \" href=\"UTD.htm?7/19/7484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17944402\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of OCD can frequently be made based upon plain radiographic findings of the characteristic bony fragment (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85768 \" href=\"UTD.htm?3/18/3362\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85769 \" href=\"UTD.htm?2/41/2704\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85770 \" href=\"UTD.htm?42/18/43298\">",
"       image 4",
"      </a>",
"      ). Suggestive clinical findings include gradually worsening joint pain over several months in active patients or, for OCD of the talus, lingering pain after an ankle inversion injury. Bony tenderness over the typical locations (medial femoral condyle, anterolateral elbow, or medial or lateral talar dome), or with advanced disease, popping, catching, or locking of the joint may be elicited. (See",
"      <a class=\"local\" href=\"#H2510300\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several conditions have clinical features that overlap with OCD. Most can be identified by a careful history and physical examination and plain radiographs. (See",
"      <a class=\"local\" href=\"#H21753968\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     DeLee JC, Drez Jr D, Miller MD. DeLee &amp; Drez's Orthopaedic Sports Medicine Principles and Practice, 2nd, Elsevier Science, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/2\">",
"      Obedian RS, Grelsamer RP. Osteochondritis dissecans of the distal femur and patella. Clin Sports Med 1997; 16:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/3\">",
"      Petrie PW. Aetiology of osteochondritis dissecans. Failure to establish a familial background. J Bone Joint Surg Br 1977; 59:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/4\">",
"      BERNDT AL, HARTY M. Transchondral fractures (osteochondritis dissecans) of the talus. J Bone Joint Surg Am 1959; 41-A:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/5\">",
"      Dipaola JD, Nelson DW, Colville MR. Characterizing osteochondral lesions by magnetic resonance imaging. Arthroscopy 1991; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/6\">",
"      Guhl JF. Arthroscopic treatment of osteochondritis dissecans. Clin Orthop Relat Res 1982; :65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/7\">",
"      Robertson W, Kelly BT, Green DW. Osteochondritis dissecans of the knee in children. Curr Opin Pediatr 2003; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/8\">",
"      Chambers HG, Shea KG, Carey JL. AAOS Clinical Practice Guideline: diagnosis and treatment of osteochondritis dissecans. J Am Acad Orthop Surg 2011; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     Essentials of Musculoskeletal Care, 3rd, Griffin LY.  (Ed), American Academy of Orthopedic Surgeons, Rosemont 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/10\">",
"      Uozumi H, Sugita T, Aizawa T, et al. Histologic findings and possible causes of osteochondritis dissecans of the knee. Am J Sports Med 2009; 37:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/11\">",
"      Thompson JP, Loomer RL. Osteochondral lesions of the talus in a sports medicine clinic. A new radiographic technique and surgical approach. Am J Sports Med 1984; 12:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/12\">",
"      Naumetz VA, Schweigel JF. Osteocartilagenous lesions of the talar dome. J Trauma 1980; 20:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/13\">",
"      Schenck RC Jr, Goodnight JM. Osteochondritis dissecans. J Bone Joint Surg Am 1996; 78:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/14\">",
"      Onoda S, Sugita T, Aizawa T, et al. Osteochondritis dissecans of the knee in identical twins: a report of two cases. J Orthop Surg (Hong Kong) 2012; 20:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/15\">",
"      Kocher MS, Tucker R, Ganley TJ, Flynn JM. Management of osteochondritis dissecans of the knee: current concepts review. Am J Sports Med 2006; 34:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/16\">",
"      Jackson DW, Silvino N, Reiman P. Osteochondritis in the female gymnast's elbow. Arthroscopy 1989; 5:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/17\">",
"      Baker CL 3rd, Baker CL Jr, Romeo AA. Osteochondritis dissecans of the capitellum. J Shoulder Elbow Surg 2010; 19:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/18\">",
"      Perumal V, Wall E, Babekir N. Juvenile osteochondritis dissecans of the talus. J Pediatr Orthop 2007; 27:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/19\">",
"      Bauer M, Jonsson K, Lind&eacute;n B. Osteochondritis dissecans of the ankle. A 20-year follow-up study. J Bone Joint Surg Br 1987; 69:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/20\">",
"      Brunton LM, Anderson MW, Pannunzio ME, et al. Magnetic resonance imaging of the elbow: update on current techniques and indications. J Hand Surg Am 2006; 31:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/21\">",
"      Letts M, Davidson D, Ahmer A. Osteochondritis dissecans of the talus in children. J Pediatr Orthop 2003; 23:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/22\">",
"      Flynn JM, Kocher MS, Ganley TJ. Osteochondritis dissecans of the knee. J Pediatr Orthop 2004; 24:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/23\">",
"      Flick AB, Gould N. Osteochondritis dissecans of the talus (transchondral fractures of the talus): review of the literature and new surgical approach for medial dome lesions. Foot Ankle 1985; 5:165.",
"     </a>",
"    </li>",
"    <li>",
"     Care of the Young Athlete, 2nd, Anderson SJ, Harris SS, Gregory AJM.  (Eds), American Academy of Pediatrics, Elk Grove Village 2010.",
"    </li>",
"    <li>",
"     Magee D. Orthopedic Physical Assessment Enhanced Edition, 4th, Saunders, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/26\">",
"      Wilson JN. A diagnostic sign in osteochondritis DISSECANS OF THE KNEE. J Bone Joint Surg Am 1967; 49:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/27\">",
"      Conrad JM, Stanitski CL. Osteochondritis dissecans: Wilson's sign revisited. Am J Sports Med 2003; 31:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/28\">",
"      Edmonds EW, Polousky J. A Review of Knowledge in Osteochondritis Dissecans: 123 Years of Minimal Evolution from K&ouml;nig to the ROCK Study Group. Clin Orthop Relat Res 2013; 471:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/29\">",
"      Moktassi A, Popkin CA, White LM, Murnaghan ML. Imaging of osteochondritis dissecans. Orthop Clin North Am 2012; 43:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/30\">",
"      Spatt JF, Frank NG, Fox IM. Transchondral fractures of the dome of the talus. J Foot Surg 1986; 25:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/31\">",
"      Pettine KA, Morrey BF. Osteochondral fractures of the talus. A long-term follow-up. J Bone Joint Surg Br 1987; 69:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/32\">",
"      Cahill BR, Phillips MR, Navarro R. The results of conservative management of juvenile osteochondritis dissecans using joint scintigraphy. A prospective study. Am J Sports Med 1989; 17:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/33\">",
"      Inoue G. Bilateral osteochondritis dissecans of the elbow treated by Herbert screw fixation. Br J Sports Med 1991; 25:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/34\">",
"      Williamson LR, Albright JP. Bilateral osteochondritis dissecans of the elbow in a female pitcher. J Fam Pract 1996; 43:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/35\">",
"      Bednarz PA, Paletta GA Jr, Stanitski CL. Bilateral osteochondritis dissecans of the knee and elbow. Orthopedics 1998; 21:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/36\">",
"      De Smet AA, Ilahi OA, Graf BK. Reassessment of the MR criteria for stability of osteochondritis dissecans in the knee and ankle. Skeletal Radiol 1996; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/37\">",
"      Heywood CS, Benke MT, Brindle K, Fine KM. Correlation of magnetic resonance imaging to arthroscopic findings of stability in juvenile osteochondritis dissecans. Arthroscopy 2011; 27:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/38\">",
"      Kijowski R, Blankenbaker DG, Shinki K, et al. Juvenile versus adult osteochondritis dissecans of the knee: appropriate MR imaging criteria for instability. Radiology 2008; 248:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/39\">",
"      Quatman CE, Quatman-Yates CC, Schmitt LC, Paterno MV. The clinical utility and diagnostic performance of MRI for identification and classification of knee osteochondritis dissecans. J Bone Joint Surg Am 2012; 94:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/40\">",
"      CAFFEY J, MADELL SH, ROYER C, MORALES P. Ossification of the distal femoral epiphysis. J Bone Joint Surg Am 1958; 40-A:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/41\">",
"      Hirschmann MT, Iranpour F, Davda K, et al. Combined single-photon emission computerized tomography and conventional computerized tomography (SPECT/CT): clinical value for the knee surgeons? Knee Surg Sports Traumatol Arthrosc 2010; 18:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/42\">",
"      Mesgarzadeh M, Sapega AA, Bonakdarpour A, et al. Osteochondritis dissecans: analysis of mechanical stability with radiography, scintigraphy, and MR imaging. Radiology 1987; 165:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/43\">",
"      Takahara M, Ogino T, Tsuchida H, et al. Sonographic assessment of osteochondritis dissecans of the humeral capitellum. AJR Am J Roentgenol 2000; 174:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/44\">",
"      Stone JW. Osteochondral Lesions of the Talar Dome. J Am Acad Orthop Surg 1996; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/45\">",
"      Scharf S. SPECT/CT imaging in general orthopedic practice. Semin Nucl Med 2009; 39:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/46\">",
"      Polousky JD. Juvenile osteochondritis dissecans. Sports Med Arthrosc 2011; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/47\">",
"      Gregersen HE, Rasmussen OS. Ultrasonography of osteochondritis dissecans of the knee. A preliminary report. Acta Radiol 1989; 30:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/48\">",
"      Kramer DE, Micheli LJ. Meniscal tears and discoid meniscus in children: diagnosis and treatment. J Am Acad Orthop Surg 2009; 17:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/49\">",
"      Carter CW, Hoellwarth J, Weiss JM. Clinical outcomes as a function of meniscal stability in the discoid meniscus: a preliminary report. J Pediatr Orthop 2012; 32:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/50\">",
"      Atanda A Jr, Shah SA, O'Brien K. Osteochondrosis: common causes of pain in growing bones. Am Fam Physician 2011; 83:285.",
"     </a>",
"    </li>",
"    <li>",
"     Patel DR, Lyne ED. Overuse injuries of elbow, forearm, wrist, and hand. In: Pediatric Practice; Sports Medicine, Patel DR, Greydanus DE, Baker RJ.  (Eds), McGraw Hill, New York 2009. p.275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13913/abstract/52\">",
"      van den Ende KI, McIntosh AL, Adams JE, Steinmann SP. Osteochondritis dissecans of the capitellum: a review of the literature and a distal ulnar portal. Arthroscopy 2011; 27:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17003 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13913=[""].join("\n");
var outline_f13_37_13913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21754098\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2509429\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21753872\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21753890\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21753897\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2510199\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21753904\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21753911\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21753918\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21753926\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17944402\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17944530\">",
"      - Other imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2510300\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21753968\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21753976\">",
"      Knee",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21753984\">",
"      - Torn meniscus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21753991\">",
"      - Symptomatic discoid meniscus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21753998\">",
"      - Medial plica syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754005\">",
"      - Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21754012\">",
"      Elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754020\">",
"      - Panner disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754027\">",
"      - Little league elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754034\">",
"      - Medial epicondyle fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754041\">",
"      - Epicondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21754048\">",
"      Talus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754056\">",
"      - Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754063\">",
"      - Os trigonum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21754070\">",
"      - Tarsal coalition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H315016\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21754098\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/17003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17003|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/56/26510\" title=\"diagnostic image 1\">",
"      Osteochondritis dissecans knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/18/3362\" title=\"diagnostic image 2\">",
"      Osteochondritis dissecans of the knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/41/2704\" title=\"diagnostic image 3\">",
"      Osteochondritis dissecans of the elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/18/43298\" title=\"diagnostic image 4\">",
"      Osteochondritis dissecans of the ankle - medial talus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/41/6800\" title=\"diagnostic image 5\">",
"      Displaced medial epicondylar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/3/38975\" title=\"diagnostic image 6\">",
"      Tarsal coalition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17003|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 1\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/51/19248\" title=\"figure 2\">",
"      Medial patellar plica test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/12/2241\" title=\"figure 3\">",
"      Knee extension test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17003|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/59/1969\" title=\"picture 1\">",
"      McMurray maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/33/36375\" title=\"picture 2\">",
"      Bones of the foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17003|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/19/7484\" title=\"table 1\">",
"      Classification of osteochondritis dissecans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=related_link\">",
"      Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=related_link\">",
"      Clinical features and management of ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22937?source=related_link\">",
"      Elbow injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=related_link\">",
"      Epicondylar and transphyseal elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=related_link\">",
"      Epicondylitis (tennis and golf elbow)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19014?source=related_link\">",
"      Management of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=related_link\">",
"      Meniscal injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=related_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1752?source=related_link\">",
"      Plica syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13914="Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults";
var content_f13_37_13914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13914/contributors\">",
"     Brad H Rovin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13914/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/37/13914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/37/13914/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/37/13914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total urinary protein excretion in the normal adult should be less than 150",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Higher rates of protein excretion that persist beyond a single measurement should be evaluated, as they often imply an increase in glomerular permeability that allows the filtration of normally non-filtered macromolecules, such as albumin.",
"   </p>",
"   <p>",
"    The assessment of urinary protein excretion and the evaluation of isolated non-nephrotic proteinuria in adults will be reviewed here. The approach to adults with nephrotic-range proteinuria or hematuria and the evaluation of children with proteinuria are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to high albuminuria (formerly called microalbuminuria), which is different from non-nephrotic proteinuria, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H424597\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H424671\">",
"    <span class=\"h2\">",
"     Isolated proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated proteinuria is defined as proteinuria without hematuria or a reduction in glomerular filtration rate (GFR). In most cases of isolated proteinuria, the patient is asymptomatic, and the presence of proteinuria is discovered incidentally by use of a dipstick during routine urinalysis. The urine sediment is unremarkable (fewer than three erythrocytes per high power field and no casts), protein excretion is less than 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (non-nephrotic), serologic markers of systemic disease are absent, and there is no hypertension, diabetes, and also no edema or hypoalbuminemia.",
"   </p>",
"   <p>",
"    This benign presentation of isolated non-nephrotic proteinuria is different from that in patients with more prominent renal disease who have one or more of the following: nephrotic-range proteinuria (&ge;3.5",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    lipiduria, edema, hypoalbuminemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an active urine sediment containing red cells (which are often dysmorphic) and red cell casts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Types of proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four basic types of proteinuria (",
"    <a class=\"graphic graphic_table graphicRef85791 \" href=\"UTD.htm?34/16/35083\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glomerular proteinuria",
"     </li>",
"     <li>",
"      Tubular proteinuria",
"     </li>",
"     <li>",
"      Overflow proteinuria",
"     </li>",
"     <li>",
"      Post-renal proteinuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glomerular proteinuria (ie, albuminuria) is identified on a urine dipstick.",
"   </p>",
"   <p>",
"    Some patients have more than one type of proteinuria. As an example, glomerular diseases, such as focal segmental glomerulosclerosis, can be associated with proximal tubular injury, leading to tubular proteinuria. In addition, patients with multiple myeloma and Bence Jones overflow proteinuria can also develop glomerular proteinuria and increased albumin excretion due to AL (primary) amyloidosis or a monoclonal immunoglobulin deposition disease.",
"   </p>",
"   <p>",
"    Measuring the urine concentrations of both albumin and total protein (with either two separate tests or with a urine protein electrophoresis) can help determine the type of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/2\">",
"     2",
"    </a>",
"    ]. In this study of 1011 patients, the ratio of the urine albumin to total protein concentration was generally less than 0.4 in patients with tubular or overflow proteinuria and greater than 0.4 in patients with predominantly glomerular proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Glomerular proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular proteinuria is due to increased filtration of macromolecules (such as albumin) across the glomerular capillary wall. This is a sensitive marker for the presence of glomerular disease. The proteinuria associated with diabetic nephropathy and other glomerular diseases, as well as more benign causes, such as orthostatic or exercise-induced proteinuria, fall into this category. Most patients with benign causes of isolated proteinuria excrete less than 1 to 2",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Tubular proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-molecular-weight proteins, such as beta2-microglobulin, immunoglobulin light chains, retinol-binding protein, and polypeptides derived from the breakdown of albumin, have molecular weights that are generally under 25,000 Daltons in comparison to the 69,000 Dalton molecular weight of albumin. These smaller proteins can be filtered across the glomerulus and are then almost completely reabsorbed in the proximal tubule. Interference with proximal tubular reabsorption, due to a variety of tubulointerstitial diseases or even some primary glomerular diseases, can lead to increased excretion of these smaller proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tubular proteinuria is often not diagnosed clinically since the dipstick for protein is not highly sensitive for the detection of proteins other than albumin and because the quantity of non-albumin proteins excreted is relatively low. The increased excretion of immunoglobulin light chains (or Bence Jones proteins) in tubular proteinuria is mild, polyclonal (both kappa and lambda), and not injurious to the kidney. This is in contrast to the monoclonal and potentially nephrotoxic nature of the light chains in the overflow proteinuria seen in multiple myeloma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Overflow proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased excretion of low-molecular-weight proteins can occur with marked overproduction of a particular protein, leading to increased glomerular filtration and excretion. This is almost always due to immunoglobulin light chains in multiple myeloma but may also be due to lysozyme (in acute myelomonocytic leukemia), myoglobin (in rhabdomyolysis), or free hemoglobin (in intravascular hemolysis) that is not bound to haptoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/6\">",
"     6",
"    </a>",
"    ]. In these settings, the filtered load is increased to a level that exceeds the normal proximal reabsorptive capacity. Patients with myeloma kidney also may develop a component of tubular proteinuria since the excreted light chains may be toxic to the tubules, leading to diminished reabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188516482\">",
"    <span class=\"h3\">",
"     Post-renal proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation in the urinary tract, which can occur with urinary tract infection, can give rise to increases in urinary protein excretion. The excreted proteins are generally non-albumin (often IgA or IgG), and only small amounts are excreted. Leukocyturia is frequently present in such patients. Patients with nephrolithiasis or tumors of the urinary tract may also have proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265924166\">",
"    <span class=\"h2\">",
"     Amounts of proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal individuals, low-molecular-weight proteins and small amounts of albumin are filtered by the glomerulus. The actual amount of albumin filtered each day in humans is controversial. The majority view is that no more than about 2 to 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of albumin are filtered normally, but some investigators claim that as much as 200 g of albumin are filtered each day (with nearly all of the filtered albumin \"reclaimed\" in the early proximal tubule) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/7\">",
"     7",
"    </a>",
"    ]. The filtered proteins enter the proximal tubule where they are almost completely reabsorbed and then catabolized by the proximal tubular cells. Some of the catabolized proteins (including albumin) are excreted as polypeptides in the urine. These are not detected by dipstick or the immunonephelometric albumin-specific assays but by chromatographic assays. The net result is the normal daily protein excretion of less than 150 mg (usually 40 to 80 mg), of which approximately about 4 to 7 mg is intact, immunoreactive albumin.",
"    <sup>",
"     &nbsp;",
"    </sup>",
"   </p>",
"   <p>",
"    Previously, abnormal proteinuria was generally defined as the excretion of more than 150 mg of total protein per day. However, it is now clear that early renal disease is reflected by lesser degrees of proteinuria, particularly increased amounts of albuminuria.",
"   </p>",
"   <p>",
"    The normal rate of albumin excretion is less than 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     mcg/min);",
"    </span>",
"    the rate is about 4 to 7",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (3 to 5",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    in healthy young adults and increases with age and with an increase in body weight. Persistent albumin excretion between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    is called high albuminuria (formerly called microalbuminuria). In patients with diabetes, this is usually indicative of incipient diabetic nephropathy (unless there is a coexisting renal disease). In non-diabetics, the presence of high albuminuria is associated with an increased risk for cardiovascular disease.",
"   </p>",
"   <p>",
"    Albumin excretion above 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    is considered overt proteinuria or very high albuminuria (formerly called macroalbuminuria), the level at which the standard dipstick becomes positive. At this level, much of the protein in the urine consists of albumin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DETECTION AND MEASUREMENT OF TOTAL URINARY PROTEIN EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two semiquantitative methods are available to screen patients for proteinuria. These are the standard urine dipstick and the precipitation of urine proteins with sulfosalicylic acid (SSA). Neither method is quantitative, and, if abnormal proteinuria is suggested by either technique, proteinuria should be quantified using a timed urine collection (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Quantitative measurement'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H424081\">",
"    <span class=\"h2\">",
"     Semiquantitative measurement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Standard urine dipstick",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard urine dipstick primarily detects albumin but is relatively insensitive to non-albumin proteins. Thus, a positive dipstick usually reflects glomerular proteinuria. SSA can be used for detection of tubular or overflow proteinuria. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Sulfosalicylic acid test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The dipstick is very specific but not sensitive to low levels of albumin excretion. The lower limit of detection is a urine albumin concentration of approximately 10 to 20",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Thus, patients with high albuminuria (formerly called microalbuminuria) will not usually be identified by this method unless the urine is highly concentrated. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Issues with measuring urine albumin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Dipstick grading (negative to 4+, based upon increasing intensity of color changes) is only semiquantitative and is highly dependent upon urine concentration. Limited data suggest that using the urine-specific gravity to judge urine concentration may improve the ability to identify abnormal proteinuria with the dipstick [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one study of more than 2000 patients, for example, a urine dipstick for proteinuria of 2+ or higher was predictive of significant proteinuria (urine protein-to-creatinine ratio (UPCR) greater than or equal to 500",
"    <span class=\"nowrap\">",
"     mg/g)",
"    </span>",
"    regardless of the specific gravity; however, a urine dipstick for proteinuria of trace or 1+ was only predictive of significant proteinuria if the specific gravity was 1.025 or less [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False-positive urine dipstick results may occur in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the use of iodinated radiocontrast agents [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/10\">",
"       10",
"      </a>",
"      ]. Thus, the urine should not be tested for protein with the standard dipstick for at least 24 hours after a contrast study.",
"     </li>",
"     <li>",
"      With a highly alkaline urine (pH greater than 8) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the presence of gross hematuria and a urocit greater than 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When various antiseptics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      , benzalkonium) are used for clean-catch urine samples [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sulfosalicylic acid test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the urine dipstick, which primarily detects albumin, SSA detects",
"    <strong>",
"     all",
"    </strong>",
"    proteins in the urine at a sensitivity of 5 to 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/1\">",
"     1",
"    </a>",
"    ]. Use of SSA is primarily indicated in patients who present with acute kidney injury, a benign urinalysis, and a negative or trace dipstick, a setting in which myeloma kidney should be excluded. A significantly positive SSA test in conjunction with a negative dipstick usually indicates the presence of non-albumin proteins in the urine, most often immunoglobulin light chains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SSA test is performed by mixing one part urine supernatant (eg, 2.5 mL) with three parts of 3 percent SSA and grading the resultant turbidity according to the following schema (the numbers in parentheses represent the approximate protein concentration) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      0 = no turbidity (0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Trace = slight turbidity (1 to 10",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      1+ = turbidity through which print can be read (15 to 30",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      2+ = white cloud without precipitate through which heavy black lines on a white background can be seen (40 to 100",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      3+ = white cloud with fine precipitate through which heavy black lines cannot be seen (150 to 350",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      4+ = flocculent precipitate (&gt;500",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to the standard urine dipstick, the SSA test will record false-positive results in the presence of many of the commonly used iodinated radiocontrast agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/10\">",
"     10",
"    </a>",
"    ]. How this occurs is not clear, but protein excretion may be overestimated by as much as 1.5 to 2",
"    <span class=\"nowrap\">",
"     g/L.",
"    </span>",
"    Thus, the urine should not be tested for protein for at least 24 hours after a contrast study. False-positive results may also occur in the presence of penicillins, sulfisoxazole, and with gross hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H424310\">",
"    <span class=\"h3\">",
"     Urinary lysozyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the SSA and urine dipstick tests can detect urinary lysozyme, the production and excretion of which may be increased in patients with acute monocytic or myelocytic leukemia. Total lysozyme excretion is usually below 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    but can exceed 4.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, lysozyme excretion should be measured in patients who have a persistently positive urine dipstick for proteinuria in the absence of albuminuria, particularly if other signs of the nephrotic syndrome (such as edema and hyperlipidemia) are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quantitative measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the degree of protein excretion is a central part of the evaluation of patients with acute and chronic kidney diseases and in patients incidentally noted to have persistent proteinuria by a semiquantitative method. The quantity of protein excretion is clinically important for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with the benign forms of isolated proteinuria excrete less than 1 to 2",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      The degree of proteinuria is prognostically important in patients with primary and secondary glomerular diseases; higher degrees of proteinuria are associated with a more rapid progression to kidney failure, even in the absence of nephrotic syndrome.",
"     </li>",
"     <li>",
"      The degree of proteinuria is used to monitor the response to therapy, as with immunosuppressive drugs for primary and secondary glomerular diseases or inhibition of the renin-angiotensin system to slow the progression of proteinuric chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H424370\">",
"    <span class=\"h3\">",
"     24-hour versus spot urine collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent proteinuria should undergo a quantitative measurement of total protein excretion. The gold standard for measurement of protein excretion is a 24-hour urine collection, with the normal value being less than 150",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The major limitations of measuring protein excretion in a 24-hour urine collection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is cumbersome for patients.",
"     </li>",
"     <li>",
"      It is often collected incorrectly. (Over- and under-collections are common.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adequacy of the collection can be estimated by quantifying the 24-hour urine creatinine and comparing this value to the expected urine creatinine. As a general rule in adults under the age of 50 years, daily creatinine excretion should be 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177 to 221",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    of lean body weight in men and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    of lean body weight in women. From the ages of 50 to 90 years, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men, lower in women) due primarily to a fall in muscle mass. Formulas that incorporate race and weight with or without serum phosphorous in addition to age and sex may improve the estimation of creatinine excretion. This is discussed elsewhere in more detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20663247#H20663247\">",
"     \"Assessment of kidney function\", section on 'Limitations of using creatinine clearance'",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the limitations of a 24-hour urine collection, a number of shortcuts have been proposed. These shortcuts generally involve measuring the ratio of protein to creatinine (or occasionally the urine albumin-to-creatinine ratio [UACR]) in urine specimens of less than 24 hours' duration. Most commonly, the urine protein-to-creatinine ratio (UPCR) in a spot first- or second-morning urine sample after avoiding exercise is used to estimate 24-hour proteinuria and to follow the effects of treatment in patients with proteinuric kidney diseases. Usually, the urine protein concentration in a spot sample is measured in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and is divided by the urine creatinine concentration also measured in",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    yielding a dimensionless number that estimates the 24-hour protein excretion in grams per day (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/16-24\">",
"     16-24",
"    </a>",
"    ]. If SI units are used, the value for the UPCR (or UACR) is divided by 8.8. As an example, a UACR of 30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine is equivalent to 3.4",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    creatinine.",
"   </p>",
"   <p>",
"    The UPCR is easy for patients and providers, and the correlation with daily protein excretion is reasonably good on the population level (",
"    <a class=\"graphic graphic_figure graphicRef63722 \" href=\"UTD.htm?33/38/34413\">",
"     figure 1",
"    </a>",
"    ). However, the UPCR may produce errors when applied to the individual patient, especially in those who consistently excrete much more (or less) than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of creatinine or in those who are losing or gaining muscle mass. (See",
"    <a class=\"local\" href=\"#H425173\">",
"     'Limitations of the UPCR and UACR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The UPCR and the UACR in spot urine samples are both supported by Kidney Disease: Improving Global Outcomes (KDIGO) as appropriate methods to ascertain kidney damage and aid in the diagnosis of chronic kidney disease. Some devices allow for quantification of urine albumin in spot urine specimens at the point of service (ie, in the clinic rather than the laboratory) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/25\">",
"     25",
"    </a>",
"    ], although these devices are not widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link&amp;anchor=H27258566#H27258566\">",
"     \"Definition and staging of chronic kidney disease\", section on 'Kidney damage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425173\">",
"    <span class=\"h4\">",
"     Limitations of the UPCR and UACR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the UPCR correlates well with 24-hour urine protein excretion on the population level, its usefulness in predicting the true 24-hour protein excretion in any given individual is debatable (",
"    <a class=\"graphic graphic_figure graphicRef63722 \" href=\"UTD.htm?33/38/34413\">",
"     figure 1",
"    </a>",
"    ). There are two major limitations of using random spot urine samples to quantify proteinuria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The UPCR and UACR are heavily influenced by the urine creatinine concentration (the denominator of the ratio) and therefore by the total daily creatinine production.",
"     </li>",
"     <li>",
"      Urine protein excretion can vary throughout the day (especially resulting from exercise and posture) and from day to day [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425226\">",
"    <span class=\"h5\">",
"     Influence of the urine creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UPCR is useful on the population level because the average 24-hour urine creatinine excretion for the population is approximately 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (11.4",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . Since the denominator of the UPCR is in grams of creatinine (ie, grams of protein per 1 gram of creatinine), the UPCR is an accurate estimate of 24-hour proteinuria only in someone who excretes 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of creatinine.",
"   </p>",
"   <p>",
"    However, the accuracy of the ratio is diminished if creatinine excretion is either markedly higher or lower than the average population value of 1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In individuals with large muscle mass, in whom creatinine excretion may be much higher than 1000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the UPCR (or UACR) will",
"      <strong>",
"       underestimate",
"      </strong>",
"      proteinuria.",
"     </li>",
"     <li>",
"      In a cachectic patient or a patient with small muscle mass, in whom creatinine excretion may be much lower than 1000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the UPCR (or UACR) will",
"      <strong>",
"       overestimate",
"      </strong>",
"      proteinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following studies illustrate how variability in the urine creatinine among individuals can create erroneous estimates of 24-hour proteinuria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 16,000 men and women representative of the United States population, urine creatinine concentrations were significantly higher among non-Hispanic blacks and Mexican Americans than among non-Hispanic whites and significantly higher among men than women [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/27\">",
"       27",
"      </a>",
"      ]. Thus, the UPCR may systematically underestimate 24-hour proteinuria in blacks, in Hispanics, and in men, while overestimating proteinuria in whites and in women.",
"     </li>",
"     <li>",
"      In a population-based cohort of 2627 Europeans, the spot UACR systematically underestimated the 24-hour albumin excretion in men (median 4.3 versus 7.4",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, lower body weight and older age were associated with higher spot UACR values independent of the true 24-hour albumin excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425233\">",
"    <span class=\"h5\">",
"     Variability of protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine protein excretion can vary throughout the day [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. Because of this diurnal variation in protein excretion, a random spot UPCR may erroneously estimate 24-hour proteinuria, even if a patient excretes exactly 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of creatinine.",
"   </p>",
"   <p>",
"    As an example, assume that a patient with lupus has a true 24-hour protein excretion that is stable at 2",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In such patients, protein excretion is approximately 50 percent higher during the middle of the day than it is during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/31\">",
"     31",
"    </a>",
"    ]. Assume that the patient provides her clinician with a first-morning voided spot urine specimen (which reflects overnight protein excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/30\">",
"     30",
"    </a>",
"    ]) and, one month later, provides a spot urine specimen during a mid-afternoon clinic visit. The UPCR is 1.6",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    in the first urine specimen and 2.4",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    in the second. The clinician may interpret these findings to mean that the patient has worsening proteinuria even though there has been no true change. &nbsp;",
"   </p>",
"   <p>",
"    The extent to which diurnal variability in protein excretion can affect the accuracy of the UPCR was evaluated in a study of 193 patients with lupus nephritis who had both random spot and 24-hour urine collections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/32\">",
"     32",
"    </a>",
"    ]. The UPCR on the spot urine was compared with the UPCR of the 24-hour urine, rather than the 24hour protein excretion, in order to account for variations in creatinine excretion. The spot urine UPCR differed from the 24-hour UPCR by more than 15 percent in 131 patients (68 percent of all patients). In 25 percent of the patients, the spot UPCR differed from the 24-hour UPCR by more than 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425240\">",
"    <span class=\"h4\">",
"     Suggested approach to quantification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations outlined above, however, are not necessarily clinically important in patients with substantial proteinuria since the exact degree of protein excretion (eg, 3 versus 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    is less important than the reproducibility of the test and changes with therapy.",
"   </p>",
"   <p>",
"    We suggest the following approach to measuring and subsequently monitoring protein excretion, which takes into account both the greater accuracy of a complete 24-hour urine collection and the greater ease of monitoring with a spot urine specimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 24-hour urine collection should be obtained during the initial evaluation, measuring the excretion of both protein and creatinine. The completeness of the 24-hour urine collection can be estimated from creatinine excretion, as described above. (See",
"      <a class=\"local\" href=\"#H424370\">",
"       '24-hour versus spot urine collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the initial 24-hour urine collection seems complete, then the rate of protein excretion is probably an accurate estimate. The UPCR (or UACR) on this 24-hour specimen can be related to the total amount of proteinuria (or albuminuria) and also compared with a random spot UPCR or UACR. Random specimens can subsequently be used to monitor the degree of proteinuria as long as muscle mass appears stable.",
"     </li>",
"     <li>",
"      If follow-up measurements of the UPCR (or UACR) suggest that a clinically important change in protein excretion has occurred, a 24-hour urine collection should be obtained to verify the change in proteinuria before therapy is altered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Issues with measuring urine albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abnormal excretion of small amounts of albumin in the urine, designated high albuminuria (formerly called microalbuminuria), may be an early marker of kidney injury in diabetes, hypertension, and glomerular diseases and is a biomarker of cardiovascular disease risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard urine dipstick cannot detect high albuminuria unless the urine is highly concentrated. There are dipsticks especially designed to more reliably detect high albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/27\">",
"     27",
"    </a>",
"    ] that have sensitivities and specificities of 80 to 97 percent and 33 to 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/34\">",
"     34",
"    </a>",
"    ]. However, these dipsticks are not quantitative and suffer from the same issues as standard dipsticks with respect to urine concentration. Thus, high albuminuria should be quantified in a timed urine specimen, as discussed above.",
"   </p>",
"   <p>",
"    Direct measurement of albuminuria with traditional immunology-based laboratory methods, such as immunonephelometry, immunoturbidimetry, and radioimmunoassay, can produce results that vary considerably. When the same sample is measured, for example, reported values with one technique may be 1.5- to 3-fold different from that reported with another technique (eg, 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    versus 30",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. These methods may also be associated with significant false-negative rates, as some albumin components are not immunologically reactive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, high-performance liquid chromatography-based measurements are able to assess all intact urinary albumin, even immuno-nonreactive albumin, resulting in increased sensitivity and specificity and higher values for albumin excretion, even in normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/38\">",
"     38",
"    </a>",
"    ]. The high-performance liquid chromatography technique may therefore prove useful for earlier and more complete identification of patients with high albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH PROTEINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a patient has been identified as having proteinuria, a careful medical history and physical exam may reveal a cause, such as diabetes mellitus, malignancy, systemic autoimmune disease, or a prior history of kidney disease. The urine sediment should be examined for indicators of glomerular disease, such as hematuria with dysmorphic red blood cells, specifically acanthocytes; red blood cell casts; and white blood cells or white blood cell casts in the absence of infection. Lipiduria is seen in patients with nephrotic syndrome, which implies glomerular disease. The serum creatinine should be measured and the glomerular filtration rate (GFR) estimated by use of the CKD-EPI formula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient with isolated proteinuria (normal urine sediment, normal kidney function) who has no obvious etiology identified by the history and physical exam should be evaluated for transient proteinuria and orthostatic proteinuria (",
"    <a class=\"graphic graphic_algorithm graphicRef85792 \" href=\"UTD.htm?5/27/5567\">",
"     algorithm 1",
"    </a>",
"    ). If transient proteinuria and orthostatic proteinuria are ruled out, the patient is said to have persistent isolated proteinuria. The subsequent evaluation of patients with persistent isolated proteinuria usually involves referral to a nephrologist and, depending upon the degree of proteinuria and the results of other tests, a kidney biopsy (",
"    <a class=\"graphic graphic_algorithm graphicRef85792 \" href=\"UTD.htm?5/27/5567\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rule out transient proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient proteinuria is common, especially in young individuals. Transient proteinuria has been reported in 8 to 12 percent of individuals younger than 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/40,41\">",
"     40,41",
"    </a>",
"    ] and in approximately 4 percent of college-aged adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient proteinuria is diagnosed if a repeat qualitative test is no longer positive for proteinuria. These patients need no further evaluation and should be reassured that they do not have kidney disease. If proteinuria is present on subsequent examinations and is not associated with orthostatic proteinuria, then persistent isolated proteinuria is diagnosed (",
"    <a class=\"graphic graphic_algorithm graphicRef85792 \" href=\"UTD.htm?5/27/5567\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Transient proteinuria can occur with fever and exercise, perhaps mediated by angiotensin II or norepinephrine-induced alterations in glomerular permeability, as well as with symptomatic urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/3,43-45\">",
"     3,43-45",
"    </a>",
"    ]. When quantified, proteinuria in such patients is generally less than 1",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    With marked exercise, protein excretion can exceed 1.5",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    in normal subjects (which is the equivalent of more than 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    if sustained). Exercise is also associated with hematuria and occasionally red blood cell casts, suggesting that the proteinuria is likely glomerular in origin. The excretion of low-molecular-weight proteins in addition to albumin is increased. This suggests both an increase in glomerular permeability (which explains the filtration of albumin) and a reduction in proximal reabsorption (which explains the excretion of normally filtered smaller proteins) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=see_link\">",
"     \"Exercise-induced hematuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rule out orthostatic proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic proteinuria is characterized by increased protein excretion in the upright position but normal protein excretion when the patient is supine. The mechanism by which orthostatic proteinuria occurs is unclear, but neurohumoral activation and altered glomerular hemodynamics may be important. Total protein excretion is generally less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in orthostatic proteinuria but may exceed 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthostatic proteinuria is a relatively common finding in adolescents (occurring in 2 to 5 percent) but an uncommon disorder in those over the age of 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/43,46,48\">",
"     43,46,48",
"    </a>",
"    ]. It is a benign condition requiring no further evaluation or specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/47\">",
"     47",
"    </a>",
"    ]. In many patients, the condition resolves over time.",
"   </p>",
"   <p>",
"    Thus, in patients younger than 30 years who have isolated proteinuria that does not resolve with repeat testing, orthostatic proteinuria should be excluded. This can be done in one of two ways.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     first option",
"    </strong>",
"    involves collection of a split urine sample using the following procedure (",
"    <a class=\"graphic graphic_table graphicRef54304 \" href=\"UTD.htm?15/48/16140\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first-morning void is discarded.",
"     </li>",
"     <li>",
"      An upright collection is obtained during the waking hours while the patient is performing normal activities. The patient should finish this collection by voiding just prior to going to sleep.",
"     </li>",
"     <li>",
"      The patient should then assume the recumbent position and collect nighttime urine (including a void immediately after waking in the morning) into a separate container.",
"     </li>",
"     <li>",
"      The protein excretion is quantified on the upright collection (which should be abnormal) and the recumbent collection (which should be normal if the patient has orthostatic proteinuria).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A",
"    <strong>",
"     second option",
"    </strong>",
"    avoids the cumbersome 24-hour urine collection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is provided with a urine specimen cup to bring home.",
"     </li>",
"     <li>",
"      The patient should empty his or her bladder just before going to bed, after which he or she should assume the recumbent position.",
"     </li>",
"     <li>",
"      Immediately upon waking in the morning, the patient should void into the urine specimen cup, and a urine protein-to-creatinine ratio (UPCR) is calculated.",
"     </li>",
"     <li>",
"      Since the patient already has had two abnormal urine specimens (to rule out transient proteinuria), a normal UPCR in the first-morning voided urine confirms the diagnosis of orthostatic proteinuria. The drawback to this approach is that the daytime and overnight urine collections are not performed in the same 24-hour period. This drawback can be circumvented by having the patient provide another daytime (upright) urine specimen when she or he returns the first-morning (recumbent) urine specimen to the laboratory for analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that many patients with glomerular disease will have a modest reduction in protein excretion when supine. However, the diagnosis of orthostatic proteinuria requires that protein excretion be",
"    <strong>",
"     normal",
"    </strong>",
"    when supine, not merely less than when in the upright position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Persistent isolated proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough evaluation is warranted when isolated proteinuria is persistent. Persistent isolated proteinuria usually reflects an underlying renal or systemic disorder (",
"    <a class=\"graphic graphic_table graphicRef85791 \" href=\"UTD.htm?34/16/35083\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with persistent proteinuria should have the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quantification of urine protein excretion, as described above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Quantitative measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of the serum creatinine (with estimation of GFR).",
"     </li>",
"     <li>",
"      Evaluation for the existence of a paraprotein with a serum immunofixation (rather than a serum immunoelectrophoresis) and measurement of serum-free light chains. A urine protein immunoelectrophoresis is also occasionally performed.",
"     </li>",
"     <li>",
"      A renal ultrasound examination to rule out structural causes (eg, reflux nephropathy, polycystic kidney disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, all patients with persistent proteinuria that is greater than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (for total protein, or a UPCR greater than 0.5",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    creatinine) or greater than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (for albumin, or a urine albumin-to-creatinine ratio (UACR) greater than 300",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine) should be referred to a nephrologist for decisions regarding further evaluation and management (eg, kidney biopsy, discussed below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49761062\">",
"    <span class=\"h3\">",
"     Role of kidney biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A kidney biopsy should be done in all patients with proteinuria of more than 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (ie, nephrotic range) or if non-nephrotic proteinuria is associated with an active urine sediment (ie, hematuria or cellular casts) or decreased GFR.",
"   </p>",
"   <p>",
"    In patients with isolated non-nephrotic proteinuria, a kidney biopsy is usually performed if, with subsequent monitoring, the degree of proteinuria increases and persists above 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or if the patient develops new glomerular hematuria, hypertension, or a reduction in estimated GFR. In addition, a kidney biopsy may be helpful in patients with isolated non-nephrotic proteinuria to diagnose a suspected systemic process if the diagnosis cannot be made reliably any other way. An overview of the indications for kidney biopsy is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether a kidney biopsy should be performed in patients with stable isolated non-nephrotic proteinuria, no edema or hypoalbuminemia, and no suspicion for a systemic disease that could explain the proteinuria, such as lupus or amyloidosis. The following issues must be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management is unlikely to be changed in the short term. As an example, in a prospective study of 25 patients with isolated non-nephrotic proteinuria (&le;3",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      who underwent renal biopsy, a management decision was changed after renal biopsy in only 3 patients (12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/50\">",
"       50",
"      </a>",
"      ]. The cause of the proteinuria was not provided.",
"     </li>",
"     <li>",
"      However, some patients with stable isolated non-nephrotic proteinuria eventually develop a reduction in kidney function. As an example, a Japanese study in which 56,000 adults were screened for urinary abnormalities identified 151 patients with asymptomatic proteinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/51\">",
"       51",
"      </a>",
"      ]. At a mean follow-up of 5.8 years, 11 percent developed renal insufficiency, while the proteinuria disappeared in 23 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The level of persistent isolated non-nephrotic proteinuria that should be evaluated by kidney biopsy has not been well defined. We and most other nephrologists perform a biopsy in patients with non-nephrotic proteinuria of 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or more but not for proteinuria that is less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/52\">",
"     52",
"    </a>",
"    ]. Some would perform a biopsy for persistent proteinuria between 1 and 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    if there are clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serologic clues suggesting a systemic disease that might be detected by renal biopsy, such as lupus or primary amyloidosis, or if there is a possible hereditary disease, such as Fabry disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy, nephrotic-range proteinuria is associated with poor renal outcomes in patients with primary and secondary glomerular diseases, and treatments to reduce proteinuria are renoprotective. In contrast, isolated non-nephrotic proteinuria may have a much more indolent course, although a fraction of such patients eventually develop renal dysfunction.",
"   </p>",
"   <p>",
"    As an example, in a study in which mass screening for asymptomatic proteinuria or asymptomatic hematuria was performed in over 56,000 adults, 151 had isolated proteinuria on dipstick [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/51\">",
"     51",
"    </a>",
"    ]. At a mean follow-up of 5.8 years, proteinuria disappeared in 23 percent, and 11 percent developed renal insufficiency, which was defined as a creatine clearance less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a serum creatinine greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Proteinuria was less likely to disappear in the 134 individuals with both proteinuria and hematuria (8 percent), and the rate of renal insufficiency was slightly higher (15 percent).",
"   </p>",
"   <p>",
"    However, patients with higher amounts of isolated non-nephrotic proteinuria may not have an indolent course. In a general population sample of 2574 community dwelling adults, for example, approximately 40 percent of those who had dipstick proteinuria 2+ or greater (corresponding to an albumin concentration of 1",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    or higher) had a rapid decline in kidney function (defined as an annual decrease in estimated glomerular filtration rate (GFR) of 5 percent or more) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal amounts of proteinuria, even high albuminuria (formerly called microalbuminuria), is an independent and significant risk factor for all-cause mortality, cardiovascular disease, and long-term end-stage renal disease risk (",
"    <a class=\"graphic graphic_figure graphicRef58089 \" href=\"UTD.htm?27/44/28360\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"     figure 3",
"    </a>",
"    ). These data are discussed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Chronic kidney disease as an independent risk factor for CHD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H834719\">",
"    <span class=\"h1\">",
"     LIMITED ROLE OF SCREENING FOR PROTEINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual screening for proteinuria is",
"    <strong>",
"     not",
"    </strong>",
"    cost-effective in the general population of healthy individuals under age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, early detection of proteinuria may be cost-effective in high-risk patients (eg, older individuals or those with diabetes or hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/37/13914/abstract/49\">",
"     49",
"    </a>",
"    ] since the administration of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) can slow the progression of proteinuric chronic kidney disease as well as high albuminuria (formerly \"microalbuminuria\") in patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of diabetic nephropathy\", section on 'Preservation of renal function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link&amp;anchor=H18#H18\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Angiotensin inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link&amp;anchor=H13#H13\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'ACE inhibitors/ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"       \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated proteinuria is defined as proteinuria without hematuria or a reduction in glomerular filtration rate (GFR). In most cases of isolated proteinuria, the patient is asymptomatic, and the presence of proteinuria is discovered incidentally by use of a dipstick during routine urinalysis. The urine sediment is unremarkable (fewer than three erythrocytes per high power field and no casts), protein excretion is less than 3",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (non-nephrotic), serologic markers of systemic disease are absent, and there is no edema, hypertension, diabetes, or hypoalbuminemia. (See",
"      <a class=\"local\" href=\"#H424671\">",
"       'Isolated proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four basic types of proteinuria (",
"      <a class=\"graphic graphic_table graphicRef85791 \" href=\"UTD.htm?34/16/35083\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of proteinuria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Glomerular proteinuria (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Glomerular proteinuria'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Tubular proteinuria (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Tubular proteinuria'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Overflow proteinuria (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Overflow proteinuria'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Post-renal proteinuria (see",
"      <a class=\"local\" href=\"#H188516482\">",
"       'Post-renal proteinuria'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal daily protein excretion (including all proteins) is less than 150 mg (usually 40 to 80 mg). The normal rate of albumin excretion is less than 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (15",
"      <span class=\"nowrap\">",
"       mcg/min);",
"      </span>",
"      the rate is about 4 to 7",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mcg/min)",
"      </span>",
"      in healthy young adults and increases with age and with an increase in body weight. Persistent albumin excretion between 30 and 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (20 to 200",
"      <span class=\"nowrap\">",
"       mcg/min)",
"      </span>",
"      is called high albuminuria (formerly called microalbuminuria). Persistent albumin excretion above 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       mcg/min)",
"      </span>",
"      is considered overt proteinuria or very high albuminuria (formerly called macroalbuminuria), the level at which the standard dipstick becomes positive. (See",
"      <a class=\"local\" href=\"#H265924166\">",
"       'Amounts of proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two semiquantitative methods are available to screen patients for proteinuria. These are the standard urine dipstick and the precipitation of urine proteins with sulfosalicylic acid (SSA). Neither method is quantitative, and, if abnormal proteinuria is suggested by either technique, proteinuria should be quantified using a timed urine collection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Standard urine dipstick'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Sulfosalicylic acid test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with persistent proteinuria should undergo a quantitative measurement of total protein excretion. The gold standard for measurement of protein excretion is a 24-hour urine collection. The major limitations of measuring protein excretion in a 24-hour urine collection include the following: it is cumbersome for patients, and it is often collected incorrectly (over- and under-collections are common). (See",
"      <a class=\"local\" href=\"#H424370\">",
"       '24-hour versus spot urine collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most commonly, the urine protein-to-creatinine ratio (UPCR) in a spot first- or second-morning urine sample after avoiding exercise is used to estimate 24-hour proteinuria and to follow the effects of treatment in patients with proteinuric kidney diseases. Usually, the urine protein concentration in a spot sample is measured in",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and is divided by the urine creatinine concentration, also measured in",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      yielding a dimensionless number that estimates the 24-hour protein excretion in grams per day (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). If SI units are used, the value for the UPCR (or urine albumin-to-creatinine ratio [UACR]) is divided by 8.8. (See",
"      <a class=\"local\" href=\"#H424370\">",
"       '24-hour versus spot urine collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the UPCR correlates well with 24-hour urine protein excretion on the population level, its usefulness in predicting the true 24-hour protein excretion in any given individual is debatable (",
"      <a class=\"graphic graphic_figure graphicRef63722 \" href=\"UTD.htm?33/38/34413\">",
"       figure 1",
"      </a>",
"      ). There are two major limitations of using random spot urine samples to quantify proteinuria: the UPCR and UACR are heavily influenced by the urine creatinine concentration (the denominator of the ratio) and therefore by the total daily creatinine production, and urine protein excretion can vary throughout the day. (See",
"      <a class=\"local\" href=\"#H425226\">",
"       'Influence of the urine creatinine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H425233\">",
"       'Variability of protein excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following approach to measuring and subsequently monitoring protein excretion, which takes into account both the greater accuracy of a complete 24-hour urine collection and the greater ease of monitoring with a spot urine specimen (see",
"      <a class=\"local\" href=\"#H425240\">",
"       'Suggested approach to quantification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A 24-hour urine collection should be obtained during the initial evaluation, measuring the excretion of both protein and creatinine. The completeness of the 24-hour urine collection can be estimated from creatinine excretion, as described above.",
"     </li>",
"     <li>",
"      If the initial 24-hour urine collection seems complete, then the rate of protein excretion is probably an accurate estimate. The UPCR (or UACR) on this 24-hour specimen can be related to the total amount of proteinuria (or albuminuria) and also compared with a random spot UPCR or UACR. Random specimens can subsequently be used to monitor the degree of proteinuria as long as muscle mass appears stable.",
"     </li>",
"     <li>",
"      If follow-up measurements of the UPCR (or UACR) suggest that a clinically important change in protein excretion has occurred, a 24-hour urine should be performed to verify the change in proteinuria before therapy is altered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After a patient has been identified as having proteinuria, a careful medical history and physical exam may reveal a cause, such as diabetes mellitus, malignancy, systemic autoimmune disease, or a prior history of kidney disease. The urine sediment should be examined for indicators of glomerular disease, such as hematuria with dysmorphic red blood cells, specifically acanthocytes; red blood cell casts; and white blood cells or white blood cell casts in the absence of infection. Lipiduria is seen in patients with nephrotic syndrome, which implies glomerular disease. The serum creatinine should be measured and the GFR estimated by use of the CKD-EPI formula. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to the patient with proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient with isolated proteinuria (normal urine sediment, normal kidney function) who has no obvious etiology identified by the history and physical exam should be evaluated for transient proteinuria and orthostatic proteinuria (",
"      <a class=\"graphic graphic_algorithm graphicRef85792 \" href=\"UTD.htm?5/27/5567\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Rule out transient proteinuria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Rule out orthostatic proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If transient proteinuria and orthostatic proteinuria are ruled out, the patient is said to have persistent isolated proteinuria. The subsequent evaluation of patients with persistent isolated proteinuria usually involves referral to a nephrologist and, depending upon the degree of proteinuria and the results of other tests, a kidney biopsy (",
"      <a class=\"graphic graphic_algorithm graphicRef85792 \" href=\"UTD.htm?5/27/5567\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Persistent isolated proteinuria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H49761062\">",
"       'Role of kidney biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9427987\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to thank Dr. Suzanne Fletcher, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD. Pathophysiology of Renal Disease, 2nd ed, McGraw-Hill, New York 1987. p.11-16.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/2\">",
"      Smith ER, Cai MM, McMahon LP, et al. The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients. Nephrol Dial Transplant 2012; 27:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/3\">",
"      Carter JL, Tomson CR, Stevens PE, Lamb EJ. Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. Nephrol Dial Transplant 2006; 21:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/4\">",
"      Portman RJ, Kissane JM, Robson AM. Use of beta 2 microglobulin to diagnose tubulo-interstitial renal lesions in children. Kidney Int 1986; 30:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/5\">",
"      Sesso R, Santos AP, Nishida SK, et al. Prediction of steroid responsiveness in the idiopathic nephrotic syndrome using urinary retinol-binding protein and beta-2-microglobulin. Ann Intern Med 1992; 116:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/6\">",
"      Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/7\">",
"      Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007; 71:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/8\">",
"      Constantiner M, Sehgal AR, Humbert L, et al. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am J Kidney Dis 2005; 45:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/9\">",
"      Makihara N, Yamasaki M, Morita H, Yamada H. A dipstick test combined with urine specific gravity improved the accuracy of proteinuria determination in pregnancy screening. Kobe J Med Sci 2011; 56:E165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/10\">",
"      Morcos SK, el-Nahas AM, Brown P, Haylor J. Effect of iodinated water soluble contrast media on urinary protein assays. BMJ 1992; 305:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/11\">",
"      Carroll MF, Temte JL. Proteinuria in adults: a diagnostic approach. Am Fam Physician 2000; 62:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/12\">",
"      Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician 2005; 71:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/13\">",
"      Tapp DC, Copley JB. Effect of red blood cell lysis on protein quantitation in hematuric states. Am J Nephrol 1988; 8:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/14\">",
"      Rudensky B. False-positive test for protein using dipsticks: contamination with chlorhexidine antiseptic. JAMA 1981; 246:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/15\">",
"      Mok CC, Tam SC, Kwong YL. Pseudonephrotic syndrome caused by lysozymuria. Ann Intern Med 1994; 121:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/16\">",
"      Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/17\">",
"      Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/18\">",
"      Abitbol C, Zilleruelo G, Freundlich M, Strauss J. Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr 1990; 116:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/19\">",
"      Steinh&auml;uslin F, Wauters JP. Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio. Clin Nephrol 1995; 43:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/20\">",
"      Chitalia VC, Kothari J, Wells EJ, et al. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol 2001; 55:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/21\">",
"      Zelmanovitz T, Gross JL, Oliveira J, de Azevedo MJ. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care 1998; 21:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/22\">",
"      Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/23\">",
"      Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/24\">",
"      Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/25\">",
"      Lambers Heerspink HJ, Witte EC, Bakker SJ, et al. Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system. Kidney Int 2008; 74:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/26\">",
"      Naresh CN, Hayen A, Craig JC, Chadban SJ. Day-to-day variability in spot urine protein-creatinine ratio measurements. Am J Kidney Dis 2012; 60:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/27\">",
"      Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/28\">",
"      Carter CE, Gansevoort RT, Scheven L, et al. Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events. Clin J Am Soc Nephrol 2012; 7:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/29\">",
"      Redon J. Measurement of microalbuminuria--what the nephrologist should know. Nephrol Dial Transplant 2006; 21:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/30\">",
"      Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/31\">",
"      Fine DM, Ziegenbein M, Petri M, et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int 2009; 76:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/32\">",
"      Hebert LA, Birmingham DJ, Shidham G, et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract 2009; 113:c177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/33\">",
"      Birmingham DJ, Rovin BH, Shidham G, et al. Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int 2007; 72:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/34\">",
"      Comper WD, Osicka TM. Detection of urinary albumin. Adv Chronic Kidney Dis 2005; 12:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/35\">",
"      Comper WD, Jerums G, Osicka TM. Differences in urinary albumin detected by four immunoassays and high-performance liquid chromatography. Clin Biochem 2004; 37:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/36\">",
"      Giampietro O, Penno G, Clerico A, et al. Which method for quantifying \"microalbuminuria\" in diabetics? Comparison of several immunological methods (immunoturbidimetric assay, immunonephelometric assay, radioimmunoassay and two semiquantitative tests) for measurement of albumin in urine. Acta Diabetol 1992; 28:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/37\">",
"      Roberts WL, Calcote CB, Cook CB, et al. Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 1998; 273:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/38\">",
"      Busby DE, Bakris GL. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens (Greenwich) 2004; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/39\">",
"      Polkinghorne KR, Su Q, Chadban SJ, et al. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis 2006; 47:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/40\">",
"      Park YH, Choi JY, Chung HS, et al. Hematuria and proteinuria in a mass school urine screening test. Pediatr Nephrol 2005; 20:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/41\">",
"      Vehaskari VM, Rapola J. Isolated proteinuria: analysis of a school-age population. J Pediatr 1982; 101:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/42\">",
"      Topham PS, Jethwa A, Watkins M, et al. The value of urine screening in a young adult population. Fam Pract 2004; 21:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/43\">",
"      Robinson RR. Isolated proteinuria in asymptomatic patients. Kidney Int 1980; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/44\">",
"      Poortmans JR. Postexercise proteinuria in humans. Facts and mechanisms. JAMA 1985; 253:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/45\">",
"      Poortmans JR, Brauman H, Staroukine M, et al. Indirect evidence of glomerular/tubular mixed-type postexercise proteinuria in healthy humans. Am J Physiol 1988; 254:F277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/46\">",
"      Springberg PD, Garrett LE Jr, Thompson AL Jr, et al. Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med 1982; 97:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/47\">",
"      Rytand DA, Spreiter S. Prognosis in postural (orthostatic) proteinuria: forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med 1981; 305:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/48\">",
"      Sebestyen JF, Alon US. The teenager with asymptomatic proteinuria: think orthostatic first. Clin Pediatr (Phila) 2011; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/49\">",
"      Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/50\">",
"      Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/51\">",
"      Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol 1996; 45:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/52\">",
"      Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 2000; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/37/13914/abstract/53\">",
"      Clark WF, Macnab JJ, Sontrop JM, et al. Dipstick proteinuria as a screening strategy to identify rapid renal decline. J Am Soc Nephrol 2011; 22:1729.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3101 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13914=[""].join("\n");
var outline_f13_37_13914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H424597\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H424671\">",
"      Isolated proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Types of proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Glomerular proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Tubular proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Overflow proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H188516482\">",
"      - Post-renal proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265924166\">",
"      Amounts of proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DETECTION AND MEASUREMENT OF TOTAL URINARY PROTEIN EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H424081\">",
"      Semiquantitative measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Standard urine dipstick",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sulfosalicylic acid test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H424310\">",
"      - Urinary lysozyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quantitative measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H424370\">",
"      - 24-hour versus spot urine collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H425173\">",
"      Limitations of the UPCR and UACR",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H425226\">",
"      - Influence of the urine creatinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H425233\">",
"      - Variability of protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H425240\">",
"      Suggested approach to quantification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Issues with measuring urine albumin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      APPROACH TO THE PATIENT WITH PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rule out transient proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rule out orthostatic proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Persistent isolated proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49761062\">",
"      - Role of kidney biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H834719\">",
"      LIMITED ROLE OF SCREENING FOR PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9427987\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3101|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/27/5567\" title=\"algorithm 1\">",
"      Algorithm for the evaluation of proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3101|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/38/34413\" title=\"figure 1\">",
"      Urine protein creat ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/44/28360\" title=\"figure 2\">",
"      Relative risks of the main complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/46/41701\" title=\"figure 3\">",
"      Relative risks of major complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/16/35083\" title=\"table 1\">",
"      Classification and characterization of proteinuria types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/48/16140\" title=\"table 2\">",
"      Split urine collection protocol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=related_link\">",
"      Exercise-induced hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=related_link\">",
"      Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_37_13915="Ultrarush VIT";
var content_f13_37_13915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of ultrarush venom immunotherapy schedule",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (micrograms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients are observed for at least two hours after completion of the initial series of injections. The maintenance dose of 100 micrograms was then given on day 15 and once per month thereafter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004; 92:409. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13915=[""].join("\n");
var outline_f13_37_13915=null;
var title_f13_37_13916="Noninvasive evaluation of sick sinus syndrome";
var content_f13_37_13916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninvasive evaluation of sick sinus syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Evaluation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abnormal response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory ECG monitoring (24 hr monitoring, event recorders, etc)",
"       </td>",
"       <td>",
"        Correlation of symptoms with a slow rate, sinus pauses or arrest, or lower pacemaker failure as well as with the bradycaria-tachycardia syndrome",
"       </td>",
"       <td>",
"        Sampling problem in that infrequent episodes may not be captured. Event recorders with memory have been more useful.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise testing",
"       </td>",
"       <td>",
"        Unable to reach 80 percent of maximal predicted heart rate for age and sex",
"       </td>",
"       <td>",
"        Caution in presence of ischemic heart disease. HF, pulmonary disease, orthopedic problems, drugs, and patient effort make interpretation difficult.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotid sinus massage",
"       </td>",
"       <td>",
"        3 second or greater pause suggests a hypersensitive vasovagal and often vasodepressor response",
"       </td>",
"       <td>",
"        May occur with sick sinus syndrome or may by itself be responsible for syncope; also occurs in asymptomatic patients without SSS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signal-averaged P wave",
"       </td>",
"       <td>",
"        Long, low amplitude signals (&lt;4 microvolts, &gt;22 msec) suggestive of SSS",
"       </td>",
"       <td>",
"        Not commonly performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Pharmacologic interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atropine (1 or 2 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        25 percent or less increase in sinus rate or sinus rate &le;90",
"       </td>",
"       <td class=\"sublist_other\">",
"        Often equivocal results, but useful if positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Isoproterenol (2-3 &micro;g/min)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Same as atropine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Caution in presence of ischemic heart disease. Sensitivity and specificity uncertain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Noninvasive diagnostic tests used to evaluate SA nodal function in patients with the sick sinus syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13916=[""].join("\n");
var outline_f13_37_13916=null;
var title_f13_37_13917="T cell response in Graves Dz";
var content_f13_37_13917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T-cell response to peptides in Graves' disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 291px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T cells in patients with Graves' disease react with appropriately processed peptides derived from thyroid antigens. Increasing amounts of peptides results in increasing proliferation of activated T cells.",
"    <div class=\"footnotes\">",
"     CPM: counts per minute.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13917=[""].join("\n");
var outline_f13_37_13917=null;
var title_f13_37_13918="Medical therapy of active ulcerative colitis";
var content_f13_37_13918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical therapy of active ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Role",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name (United States or as noted)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily dose",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td rowspan=\"24\">",
"        Induction of remission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Topical (rectal) mesalamine*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suppository",
"       </td>",
"       <td>",
"        Canasa",
"       </td>",
"       <td>",
"        1 gram (one suppository) twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retention enema",
"       </td>",
"       <td>",
"        Rowasa",
"       </td>",
"       <td>",
"        4 grams (one 60 mL unit) twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Topical (rectal) glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrocortisone suppository",
"       </td>",
"       <td>",
"        Proctocort, Hemril",
"       </td>",
"       <td>",
"        30 mg (one suppository) twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrocortisone aerosol foam 10 percent",
"       </td>",
"       <td>",
"        Cortifoam",
"       </td>",
"       <td>",
"        90 mg (one applicatorful) twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrocortisone enema",
"       </td>",
"       <td>",
"        Cortenema, Colocort",
"       </td>",
"       <td>",
"        100 mg (one 60 mL unit) twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Oral 5-aminosalycylic acid (5-ASA) derivatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        Azulfidine, Salazopyrin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        4 to 6 grams per day in four divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Mesalamine*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Delayed release enteric coated tablet",
"       </td>",
"       <td>",
"        Asacol, Asacol HD",
"       </td>",
"       <td>",
"        2.4 to 4.8 grams daily in three divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Delayed and extended release tablet, multimatrix",
"       </td>",
"       <td>",
"        Lialda, Mezavant",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.4 to 4.8 grams daily once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Capsule containing delayed release enteric coated granules",
"       </td>",
"       <td>",
"        Apriso",
"       </td>",
"       <td>",
"        1.5 to 4.5 grams once each morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Controlled release capsule",
"       </td>",
"       <td>",
"        Pentasa",
"       </td>",
"       <td>",
"        2 to 4 grams daily in four divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Mesalamine pellets",
"       </td>",
"       <td>",
"        Salofalk",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 to 4 grams daily in one to three divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentasa sachet",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 to 4 grams daily in two to four divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olsalazine capsule",
"       </td>",
"       <td>",
"        Dipentum",
"       </td>",
"       <td>",
"        2 to 3 grams daily in two to four divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Balsalazide capsule",
"       </td>",
"       <td>",
"        Colazal",
"       </td>",
"       <td>",
"        2.25 to 6.75 grams daily in three divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone or oral prednisolone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        40 to 60 mg once each morning or in two divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravenous prednisolone",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        30 mg IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        16 to 20 mg IV every eight hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        100 mg IV every eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"15\">",
"        Maintenance of remission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Topical (rectal) mesalamine*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suppository",
"       </td>",
"       <td>",
"        Canasa",
"       </td>",
"       <td>",
"        1 gram (1 suppository) at bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enema",
"       </td>",
"       <td>",
"        Rowasa",
"       </td>",
"       <td>",
"        2 to 4 grams (30 to 60 mL) at bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Oral 5-aminosalycylic acid (5-ASA) derivatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        Azulfidine, Salazopyrin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        4 to 6 grams daily in three or four divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Mesalamine*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Delayed release enteric coated tablet",
"       </td>",
"       <td>",
"        Asacol, Asacol HD",
"       </td>",
"       <td>",
"        1.6 to 2.4 grams daily in one to three divided doses (depending upon preparation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Delayed and extended release tablet, multimatrix",
"       </td>",
"       <td>",
"        Lialda, Mezavant",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.4 grams once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Capsule containing delayed release enteric coated granules",
"       </td>",
"       <td>",
"        Apriso",
"       </td>",
"       <td>",
"        1.5 to 3 grams once each morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Controlled release capsule",
"       </td>",
"       <td>",
"        Pentasa",
"       </td>",
"       <td>",
"        1.5 to 4 grams daily in four divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Mesalamine pellets",
"       </td>",
"       <td>",
"        Salofalk",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0.75 to 4 grams daily in one to three divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentasa sachet",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 to 4 grams once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olsalazine capsule",
"       </td>",
"       <td>",
"        Dipentum",
"       </td>",
"       <td>",
"        1 gram daily in two divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Balsalazide capsule",
"       </td>",
"       <td>",
"        Colazal",
"       </td>",
"       <td>",
"        2 to 6.75 grams daily in three divided doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Sulfasalazine, mesalamine (Asacol, Pentasa, and Lialda), and balsalazide (Colazal) are approved by the US Food and Drug Administration (FDA) for treatment and maintenance of remission of active ulcerative colitis, while olsalazine (Dipentum) is approved for maintenance therapy in patients who are allergic to sulfasalazine. Encapsulated mesalamine granules (Apriso) is approved for maintenance of remission by the US FDA.",
"    <div class=\"footnotes\">",
"     5-ASA: 5-aminosalicylate; IV: intravenous; US: United States.",
"     <br/>",
"     * Mesalamine is US generic name. Mesalazine is an international generic (nonproprietary) name.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not available in US. Trade names shown are for products commonly available in areas other than US including Canada, United Kingdom, and Europe.",
"    </div>",
"    <div class=\"reference\">",
"     Data courtesy of authors with additional data from: Ord&aacute;s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13918=[""].join("\n");
var outline_f13_37_13918=null;
var title_f13_37_13919="Pulmonary LAM microscopy Low";
var content_f13_37_13919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic features of lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low magnification photomicrograph showing a portion of a cystic space in lymphangioleiomyomatosis. The periphery of the cystic space consists of alveolar septa and peribronchiolar interstitium that has been expanded by a population of spindle cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_37_13919=[""].join("\n");
var outline_f13_37_13919=null;
